UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY.DOCKET NO./TITLE	REQUEST ID
14/732,358	06/05/2015	Andrew L. Paris III	25412-0002002	163034

Acknowledgement of Loss of Entitlement to Entity Status Discount

The entity status change request below filed through Private PAIR on 04/08/2022 has been accepted.

CERTIFICATIONS:

Change of Entity Status:

X Applicant changing to regular undiscounted fee status.

NOTE: Checking this box will be taken to be notification of loss of entitlement to small or micro entity status, as applicable.

This portion must be completed by the signatory or signatories making the entity status change in accordance with 37 CFR 1.4(d)(4).

Signature:	/Jeffrey J. Barclay, Reg. No. 48,950/
Name:	Jeffrey J. Barclay
Registration Number:	48950

AO 120 (Rev. 3/04)

TO:	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court District of Massachusetts on the following ✓ Patents or Trademarks:

DOCKET NO.	DATE FILED	U.S. DISTRICT COURT
	5/25/2021	District of Massachusetts

PLAINTIFF	DEFENDANT
MILLIMAN, INC., MILLIMAN SOLUTIONS, LLC, and VIGILYTICS LLC	GRADIENT A.I. CORP., STANFORD A. SMITH, and SAMUEL CHASE PETTUS

	PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1	SEE ATTACHED		
2			
3			
4			
5			

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY Amendment Answer Cross Bill Other Pleading	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

CLERK	(BY) DEPUTY CLERK	DATE

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

AO 120 - ATTACHMENT PAGE

	PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1	U.S. Patent No. 9,118,641	Aug. 25, 2015	Vigilytics LLC
2	U.S. Patent No. 9,323,892	Apr. 26, 2016	Vigilytics LLC
3	U.S. Patent No. 9,665,685	May 30, 2017	Vigilytics LLC
4	U.S. Patent No. 9,965,651	May 8, 2018	Vigilytics LLC
5	U.S. Patent No. 10,109,375	Oct. 23, 2018	Vigilytics LLC
6	U.S. Patent No. 10,886,012	Jan. 5, 2021	Vigilytics LLC

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO.	: 10,109,375 B1
APPLICATION NO.	: 14/732358
DATED	: October 23, 2018
INVENTOR(S)	: Andrew L. Paris, III

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims

Column 12, Line 2: In Claim 14, delete "it" and insert -- if --, therefor.

Signed and Sealed this
Eleventh Day of December, 2018

Andrei Iancu
Director of the United States Patent and Trademark Office

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	: Andrew L. Paris III	Art Unit	: 2491
Patent No.	: 10,109,375	Examiner	: Evans Desrosiers
Issue Date	: October 23, 2018	Conf. No.	: 3202
Serial No.	: 14/732,358		
Filed	: June 5, 2015		

Title : DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

Attention Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION

Please issue a certificate of correction in accordance with the attached form.

The error to be corrected were made in printing by the Patent and Trademark Office, and no fee is believed to be due.

Apply any necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 11/14/18

/Natalie K Galley/
Natalie K. Galley, Ph.D.
Reg. No. 77,020

Customer Number 26161
Fish & Richardson P.C.
Telephone: +1 (617) 956-5911
Facsimile: (877) 769-7945

23833170.doc

PTO/SB/44 (09-07)
Approved for use through 08/31/2013. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO.	10,109,375
APPLICATION NO.:	14/732,358
ISSUE DATE	October 23, 2018
INVENTOR(S)	Andrew L. Paris III

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 12, line 2: In Claim 14, delete "it" and insert - - if - -, therefor.

MAILING ADDRESS OF SENDER (Please do not use customer number below):
Fish & Richardson P.C.
P.O. Box 1022
Minneapolis, MN 55440-1022

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and selection option2.

Electronic Acknowledgement Receipt

EFS ID:	34303194
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Natalie K. Galley/Cathy O'Brien
Filer Authorized By:	Natalie K. Galley
Attorney Docket Number:	25412-0002002
Receipt Date:	14-NOV-2018
Filing Date:	05-JUN-2015
Time Stamp:	09:37:21
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Certificate of Correction	RequestforCOC.pdf	129466 eb49fa3a6932d5f62582aab91c419f0bf7ba7ec2	no	2

Warnings:

Datavant Exhibit 1002

Information:	
Total Files Size (in bytes):	129466

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/732,358	10/23/2018	10109375	25412-0002002	3202

26161 7590 10/03/2018

FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment is 343 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

Andrew L. Paris III, Victor, NY;
Vigilytics LLC, Victor, NY;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

Datavant Exhibit 1002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor :	Andrew L. Paris III	Art Unit :	2491
Serial No. :	14/732,358	Examiner :	Evans Desrosiers
Filed :	June 5, 2015	Confirmation No. :	3202
		Notice of Allowance Date: June 22, 2018	
Title :	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

MAIL STOP ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INTERVIEW SUMMARY

The undersigned thanks the Examiner for having reached out to propose an Examiner's amendment in May 2018. The Applicant agreed with the amendments that are reflected in the allowed claims.

REPLY TO NOTICE OF ALLOWANCE

In response to the Notice of Allowance dated June 22, 2018, enclosed is a completed Part B - Fee(s) Transmittal.

The issue fee is being paid with this reply on the Electronic Filing System. Apply those fees and any other necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

COMMENTS ON EXAMINER'S REASONS FOR ALLOWANCE

It is recognized that in accordance with M.P.E.P. § 1302.14, the Examiner's reasons for allowance need not set forth all of the details as to why the claims are allowed. In the above-referenced application, it is not conceded that the Examiner's stated reasons for allowance are the only reasons for which the claims are allowable. The Examiner's reasons for allowance indicate that particular claim elements are not disclosed or suggested by the prior art of record, yet the claims may be patentable for other reasons as well, including the inventive combination of all of the recited claim elements. It is not conceded that the specific limitations identified by the Examiner are necessary to distinguish the art of record or to satisfy the requirements of 35 U.S.C. § 112. Moreover, the Examiner does not assert, and it would not be conceded, that the Examiner's reasons have any bearing on the patentability of claims in any other applications directed to the disclosed subject matter.

In addition, each dependent claim stands on its own and may be allowable on its own merits. In particular, each dependent claim may be allowable on the basis of a combination of some of the features recited in the dependent claim and its base claim(s), which combination of features may not include all of the limitations identified in the Examiner's reasons for allowance.

Respectfully submitted,

Date: 9/21/18

/Natalie K Galley/
Natalie K. Galley, Ph.D.
Reg. No. 77,020

Customer Number 26161
Fish & Richardson P.C.
Telephone: +1 (617) 956-5911
Facsimile: (877) 769-7945

23797370.doc

Datavant Exhibit 1002

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22314-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

26161 7590 06/22/2018

FISH & RICHARDSON P.C.
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, EFS-Web transmitted, or facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

Cathy A. O'Brien	(Depositor's name)
/Cathy A. O'Brien/	(Signature)
September 21, 2018	(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/732,358	06/05/2015	Andrew L. Paris III	25412-0002002	3202

TITLE OF INVENTION: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	$500	$0	$0	$500	09/22/2018

EXAMINER	ART UNIT	CLASS-SUBCLASS
DESROSIERS, EVANS	2491	713-168000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

[ ] Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

[ ] "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,

1 Fish & Richardson P.C.

(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

2 _____

3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE
Vigilytics LLC

(B) RESIDENCE: (CITY and STATE OR COUNTRY)
Victor, NY

Please check the appropriate assignee categories (will not be printed on the patent): [ ] Individual [X] Corporation or other private group entity [ ] Government

4a. The following fee(s) are submitted:

[X] Issue Fee

[ ] Publication Fee (No small entity discount permitted)

[ ] Advance Order - # of Copies _____

4b. Payment of Fee(s): **(Please first reapply any previously paid fee shown above)**

[ ] A check is enclosed.

[ ] Payment by credit card. Form PTO-2038 is attached.

[X] The Director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number 06-1050 (enclose an extra copy of this form).

5. **Change of Entity Status** (from status indicated above)

[ ] Applicant certifying micro entity status. See 37 CFR 1.29 **NOTE**: Absent a valid certification of Micro Entity Status (see form PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

[ ] Applicant asserting small entity status. See 37 CFR 1.27 **NOTE**: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

[ ] Applicant changing to regular undiscounted fee status. **NOTE**: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature /Natalie K Galley/ Date 9/21/18

Typed or printed name Natalie K. Galley, Ph.D. Registration No. 77,020

23797373.doc

Datavant Exhibit 1002

Electronic Patent Application Fee Transmittal

Application Number:	14732358
Filing Date:	05-Jun-2015
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Natalie K. Galley/Cathy O'Brien
Attorney Docket Number:	25412-0002002

Filed as Small Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
UTILITY APPL ISSUE FEE	2501	1	500	500

Datavant Exhibit 1002

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**500**

Electronic Acknowledgement Receipt

EFS ID:	33789476
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Natalie K. Galley/Trisha Hawley
Filer Authorized By:	Natalie K. Galley
Attorney Docket Number:	25412-0002002
Receipt Date:	21-SEP-2018
Filing Date:	05-JUN-2015
Time Stamp:	11:41:13
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$500
RAM confirmation Number	092118INTEFSW00016981061050
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Datavant Exhibit 1002

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		ReplytoNOA.pdf	153919 8f3ee57edc2be91cd614495a79fc53793d23 8848	yes	3
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Miscellaneous Incoming Letter		1	2	
	Issue Fee Payment (PTO-85B)		3	3	
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	30216 f849d3c60178 1c4dbed7d0de6852ec566f2 b0a87	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	184135		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.
National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
PO Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
14/732,358	06/05/2015	2491	880	25412-0002002	20	3

CONFIRMATION NO. 3202

CORRECTED FILING RECEIPT

26161
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

OC000000101371523

Date Mailed: 08/03/2018

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)

Andrew L. Paris III, Victor, NY;

Applicant(s)

Vigilytics LLC, Victor, NY;

Assignment For Published Patent Application

Vigilytics LLC, Victor, NY

Power of Attorney: The patent practitioners associated with Customer Number 26161

Domestic Priority data as claimed by applicant

This application is a CON of 12/827,745 06/30/2010 PAT 9118641
which claims benefit of 61/222,428 07/01/2009

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: No

Permission to Access Search Results: No

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 06/15/2015

Datavant Exhibit 1002

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 14/732,358**

Projected Publication Date: Request for Non-Publication Acknowledged

Non-Publication Request: Yes

Early Publication Request: No
**** SMALL ENTITY ****
Title

De-identifying medical history information for medical underwriting

Preliminary Class

713

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

Datavant Exhibit 1002

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

Datavant Exhibit 1002

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

26161 7590 06/22/2018
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MINNESOTA 55440-1022
UNITED STATES OF AMERICA

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	PAPER NUMBER
2491	

DATE MAILED: 06/22/2018

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/732,358	06/05/2015	Andrew L. Paris III	25412-0002002	3202

TITLE OF INVENTION: De-identifying medical history information for medical underwriting

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	$500	$0.00	$0.00	$500	09/24/2018

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

Datavant Exhibit 1002

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

26161 7590 06/22/2018
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MINNESOTA 55440-1022
UNITED STATES OF AMERICA

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/732,358	06/05/2015	Andrew L. Paris III	25412-0002002	3202

TITLE OF INVENTION: De-identifying medical history information for medical underwriting

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	$500	$0.00	$0.00	$500	09/24/2018

EXAMINER	ART UNIT	CLASS-SUBCLASS
DESROSIERS, EVANS	2491	713-168000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

❑ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

❑ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 _____
2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ❑ Individual ❑ Corporation or other private group entity ❑ Government

4a. The following fee(s) are submitted:

❑ Issue Fee

❑ Publication Fee (No small entity discount permitted)

❑ Advance Order - # of Copies _____

4b. Payment of Fee(s): **(Please first reapply any previously paid issue fee shown above)**

❑ A check is enclosed.

❑ Payment by credit card. Form PTO-2038 is attached.

❑ The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. **Change in Entity Status** (from status indicated above)

❑ Applicant certifying micro entity status. See 37 CFR 1.29

❑ Applicant asserting small entity status. See 37 CFR 1.27

❑ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

Datavant Exhibit 1002

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/732,358	06/05/2015	Andrew L. Paris III	25412-0002002	3202

26161 7590 06/22/2018

FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MINNESOTA 55440-1022
UNITED STATES OF AMERICA

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	PAPER NUMBER
2491	

DATE MAILED: 06/22/2018

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

Datavant Exhibit 1002

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Datavant Exhibit 1002

Notice of Allowability	Application No. 14/732,358	Applicant(s) Paris, Andrew L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	AIA Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☑ This communication is responsive to 04/20/2018.
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

3. ☑ The allowed claim(s) is/are 1-22 . As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see **http://www.uspto.gov/patents/init_events/pph/index.jsp** or send an inquiry to **PPHfeedback@uspto.gov.**

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

   Certified copies:

   a) ☐ All b) ☐ Some *c) ☐ None of the:

   1. ☐ Certified copies of the priority documents have been received.
   2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
   3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____ .

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file areply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____ .

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☑ Notice of References Cited (PTO-892)
2. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____.
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material _____.
4. ☑ Interview Summary (PTO-413), Paper No./Mail Date. 05/16/2018.
5. ☑ Examiner's Amendment/Comment
6. ☑ Examiner's Statement of Reasons for Allowance
7. ☐ Other _____.

/EVANS DESROSIERS/
Primary Examiner, Art Unit 2491

Datavant Exhibit 1002

Notice of Pre-AIA or AIA Status

1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

DETAILED ACTION

2. This communication is in response to the applicant's Request for Continued Examination filed on 04/20/2018 in which Claims 1-22 are presented for examination.

Status of claims

3. Claims 1-22 are pending; of which claims 1-22 are allowed.

Terminal Disclaimer

4. The terminal disclaimer filed on 05/22/2018 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of the US Patent No. 9,118,641 has been reviewed and is accepted. The terminal disclaimer has been recorded.

EXAMINER'S AMENDMENT

5. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 FR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given during a telephone interview on 05/17/2018 by Applicant's representative Natalie Galley (Reg. No. L1010).

6. The application has been amended as follows:

1. (Currently Amended) A computer-implemented method comprising:

receiving a request message for healthcare information that characterizes a group composed of a number of individuals, wherein the request message for healthcare information is sent to an encryption server that is configured to determine if the number of individuals in the request is at least a defined minimum number of individuals, and wherein the request message includes a batch number and at least one report option;

producing, by a processor of an encryption server, a unique request token from identifying data for each individual included in the group, wherein the request tokens are encrypted before being transmitted over a network;

comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens;

producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

14. (Currently Amended) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request message for healthcare information that characterizes a group composed of a number of individuals, wherein the request message for healthcare information is sent to an encryption server that is configured to determine if the number of individuals in the request is at least a defined minimum number of

individuals, and wherein the request message includes a batch number and at least one report option;

producing, by a processor of an encryption server, a unique request token from identifying data for each individual included in the group , wherein the request tokens are encrypted before being transmitted over a network;

comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens;

producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

REASON FOR ALLOWANCE

7. The following is an examiner's statement of reasons for allowance:

None of the prior arts of record individually or in combination explicitly teach or fairly suggest the each and every claimed limitation of the current invention as amended by the applicant, especially the independent claim include "receiving a request message for healthcare information that characterizes a group composed of a number of individuals, wherein the request message for healthcare information is sent to an encryption server that is configured to determine if the number of individuals in the request is at least a defined minimum number of individuals, and wherein the request message includes a batch number and at least one report option; producing, by a processor of an encryption

server, a unique request token from identifying data for each individual included in the group , wherein the request tokens are encrypted before being transmitted over a network."

The closest prior art of record (McLaughlin (U.S 20090024416 A1) which; describes "security of the patient's records are controlled by the patient."

Further, (Pugh U.S. 20060229919 A1) has been considered to compensate the deficiencies of McLaughlin. Pugh is directed toward "maintaining and selectively accessing medical histories; but does not cure the deficiencies of McLaughlin.

Therefore, McLaughlin and Pugh individually or in combination explicitly teach or fairly suggest or render obvious the each and every claimed limitation of the current invention as presented by the applicant, especially the limitation of "receiving a request message for healthcare information that characterizes a group composed of a number of individuals, wherein the request message for healthcare information is sent to an encryption server that is configured to determine if the number of individuals in the request is at least a defined minimum number of individuals, and wherein the request message includes a batch number and at least one report option; producing, by a processor of an encryption server, a unique request token from identifying data for each individual included in the group , wherein the request tokens are encrypted before being transmitted over a network."

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EVANS DESROSIERS whose telephone number is (571)270-5438. The examiner can normally be reached on Monday -Thursday 7:00 am - 5:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ashok B. Patel can be reached on 5712723972. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/EVANS DESROSIERS/
Primary Examiner, Art Unit 2491

Examiner-Initiated Interview Summary	Application No. 14/732,358	Applicant(s) Paris, Andrew L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	AIA Status No

All participants (applicant, applicant's representative, PTO personnel):

(1) EVANS DESROSIERS. (3) _____.

(2) Natalie Galley. (4) _____.

Date of Interview: 16 May 2018.

Type: ☑ Telephonic ☐ Video Conference
☐ Personal [copy given to: ☐ applicant ☐ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☑ No.
If Yes, brief description: _____.

Issues Discussed ☐ 101 ☐ 112 ☐ 102 ☐ 103 ☑ Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: 1-22.

Identification of prior art discussed: N/A.

Substance of Interview
(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

Amendments have been prepared by the Examiner (See attached) and reached out to Applicant representative and proposed the amendments to Applicant representative Mrs. Natalie Galley In response, the Applicant representative agreed with the Examiner's amendments and authorized the Examiner's to enter the amendment in order to place the application in condition for allowance. ..

Applicant recordation instructions: It is not necessary for applicant to provide a separate record of the substance of interview.

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☑ Attachment

/EVANS DESROSIERS/ Primary Examiner, Art Unit 2491	

Datavant Exhibit 1002

Notice of References Cited	Application/Control No. 14/732,358	Applicant(s)/Patent Under Reexamination Paris, Andrew L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-20060229919-A1	10-2006	Pugh; Timothy	G06Q50/22	705/3
*	B	US-20090024416-A1	01-2009	McLaughlin; Mark R.	G06Q50/22	705/3
	C					
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Datavant Exhibit 1002

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14/732,358	Paris, Andrew L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

CPC						
Symbol					**Type**	**Version**
G16H	/	10	/	60	F	2018-01-01
G06F	/	19	/	322	I	2013-01-01

CPC Combination Sets							
Symbol					**Type**	**Set**	**Ranking**	**Version**
	/		/					

NONE		Total Claims Allowed:	
(Assistant Examiner)	(Date)	22	
/EVANS DESROSIERS/ Primary Examiner, Art Unit 2491	30 May 2018	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	1

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14/732,358	Paris, Andrew L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

INTERNATIONAL CLASSIFICATION					
CLAIMED					
H04L	/	9	/	32	

NON-CLAIMED					
G06F	/	21	/	00	

US ORIGINAL CLASSIFICATION	
CLASS	**SUBCLASS**
713	168

CROSS REFERENCES(S)						
CLASS	**SUBCLASS (ONE SUBCLASS PER BLOCK)**					

NONE (Assistant Examiner) (Date)	**Total Claims Allowed:** 22	
/EVANS DESROSIERS/ Primary Examiner, Art Unit 2491 (Primary Examiner) 30 May 2018 (Date)	O.G. Print Claim(s) 1	O.G. Print Figure 1

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14/732,358	Paris, Andrew L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

☑ Claims renumbered in the same order as presented by applicant ☐ CPA ☑ T.D. ☐ R.1.47

CLAIMS

Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1		10		19										
	2		11		20										
	3		12		21										
	4		13		22										
	5		14												
	6		15												
	7		16												
	8		17												
	9		18												

NONE (Assistant Examiner)	(Date)	**Total Claims Allowed:** 22	
/EVANS DESROSIERS/ Primary Examiner, Art Unit 2491 (Primary Examiner)	30 May 2018 (Date)	O.G. Print Claim(s) 1	O.G. Print Figure 1

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14/732,358	Paris, Andrew L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☑ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	07/11/2017	11/10/2017	05/30/2018						
	1	✓	✓	=						
	2	✓	✓	=						
	3	✓	✓	=						
	4	✓	✓	=						
	5	✓	✓	=						
	6	✓	✓	=						
	7	✓	✓	=						
	8	✓	✓	=						
	9	✓	✓	=						
	10	✓	✓	=						
	11	✓	✓	=						
	12	✓	✓	=						
	13	✓	✓	=						
	14	✓	✓	=						
	15	✓	✓	=						
	16	✓	✓	=						
	17	✓	✓	=						
	18	✓	✓	=						
	19	✓	✓	=						
	20	✓	✓	=						
	21		✓	=						
	22		✓	=						

Datavant Exhibit 1002

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14/732,358	Paris, Andrew L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

CPC - Searched*		
Symbol	Date	Examiner
H04L63/08, H04L/0428	7/11/2017	ED
H04L63/08, H04L/0428	11/10/2017	ED
H04L63/08, H04L/0428	05/30/2018	ED

CPC Combination Sets - Searched*		
Symbol	Date	Examiner

US Classification - Searched*			
Class	Subclass	Date	Examiner
380	28-30,255-283	7/11/2017	ED
713	150-154,160-167,189-193	7/11/2017	ED
380	28-30,255-283	11/10/2017	ED
713	150-154,160-167,189-193	11/10/2017	ED
713	150-154,160-167,189-193	05/30/2018	ED

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	Date	Examiner
EAST:USPGPUB;USPAT;USOCR;FPRS;EPO;JPO;IBM_TDB	7/11/2017	ED
EAST:USPGPUB;USPAT;USOCR;FPRS;EPO;JPO;IBM_TDB	11/10/2017	ED
EAST:USPGPUB;USPAT;USOCR;FPRS;EPO;JPO;IBM_TDB	05/30/2018	ED

Datavant Exhibit 1002

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14/732,358	Paris, Andrew L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner
713	168	05/30/2018	ED
H04L	63/08	05/30/2018	ED

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	3	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:15
S2	744	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:18
S3	208	S2 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:20
S4	19	S3 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:22
S5	30884	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S6	0	S3 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S7	0	S4 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S8	2	S2 and S5	US-	OR	OFF	2012/05/30

Datavant Exhibit 1002

			PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			15:26
S9	1099	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:30
S10	10	S5 and S9	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:31
S11	8319	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:58
S12	278	S11 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:18
S13	32	S11 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:20
S14	62	S11 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:28
S15	55	S14 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:29
S16	2	("10825352").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	OFF	2012/05/30 17:21

Datavant Exhibit 1002

			IBM_TDB			
S17	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:56
S18	60	S17 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:57
S19	2	S18 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:58
S20	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S21	60	S20 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S22	38	S21 and (number with (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:25
S23	8	S21 and (number near5 (patient individual) with (group set))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:27
S24	5838	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:52
S25	180	S24 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR;	OR	OFF	2012/05/31 16:53

			FPRS; EPO; JPO; IBM_TDB			
S26	3325	S25 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:54
S27	6	S25 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:55
S28	222	S24 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S29	346	S24 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S30	6	S24 and ((minimum maximum) near5 number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:05
S31	352	S24 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:07
S32	119	S31 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S33	112	S32 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S34	5528	S24 and ((determin$5 comput$5) (number quantity) near5 (patient	US-PGPUB;	OR	OFF	2012/05/31 17:12

Datavant Exhibit 1002

		individual) with group)	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S35	28	S24 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S36	26	S35 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S37	180811	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S38	379	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S39	236	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S40	0	S39 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S41	30	S39 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S42	28	S41 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17

S43	109322	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:41
S44	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S45	31843	S43 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S46	31843	S43 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S47	2	S43 and (minimum near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S48	97352	S43 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S49	6	S43 and (determin$5 near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S50	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:50
S51	138	S50 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2012/05/31 17:51

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S52	30901	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S53	0	S42 and S52	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S54	3	(("7304852") or ("6041347") or ("20040205540")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:03
S55	207	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:06
S56	36	S55 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S57	33	S56 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S58	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:47
S59	36721	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:48
S60	4	S58 and S59	US-PGPUB; USPAT;	OR	OFF	2013/12/06 10:48

Datavant Exhibit 1002

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S61	45185	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:50
S62	7	S58 and S61	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:51
S63	5	S62 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:52
S64	127	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:03
S65	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:05
S66	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S67	61	S66 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S68	0	S67 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:22
S69	33	S67 and (un$1authoriz$3)	US-	OR	OFF	2013/12/06

Datavant Exhibit 1002

			PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			11:23
S70	4	S61 and S67	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:32
S71	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:28
S72	467	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:50
S73	1	S71 and S72	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:51
S74	40	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S75	0	S71 and S74	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S76	35	S74 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S77	0	S71 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	OFF	2013/12/12 11:57

Datavant Exhibit 1002

			IBM_TDB			
S78	985	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S79	0	S78 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58
S80	5	(report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58
S81	188	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:06
S82	10137562	(produc$5 display) ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S83	2	(produc$5 display) near5 ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S84	167	S81 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S85	2	(((information data record)) same without near5 (patient individual) near5 authoriz$5).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S86	128	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR;	OR	OFF	2013/12/12 12:46

Datavant Exhibit 1002

			FPRS; EPO; JPO; IBM_TDB			
S87	0	S86 and un$1attainab$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S88	45317	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:48
S89	8	S86 and S88	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:48
S90	8	S89 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:49
S91	4	(("2007033405") or ("2003123668") or ("2001046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S92	3	(("20070033405") or ("20030123668") or ("20010046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S93	4	US-20040143403-$.DID. OR US-20060020611-$.DID. OR US-20080133273-$.DID. OR US-20090287502-$.DID.	US-PGPUB; USPAT	OR	OFF	2014/05/02 10:47
S94	2	("20030037054").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 13:40
S95	1	("6988075").PN.	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2014/08/22 14:30

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S96	3	(("20110225007") or ("20090070146")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:01
S97	5248	(Extending adj the adj Health adj Insurance adj Portability adj Accountability adj Act) (HIPAA)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:05
S98	209	(((information data record)) same without near5 (patient individual) near5 authoriz$5)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:06
S99	209	(((information data record)) same without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S100	264	(((information data record)) same without near5 (patient individual group) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S101	52	S97 and S100	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S102	43	S101 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:08
S103	2934	705/1,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:37
S104	19817	705/1,2,3,4,5.ccls.	US-PGPUB; USPAT;	OR	OFF	2014/08/22 15:37

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S105	3	(Internet adj medical adj information adj system (IMED)) same (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:39
S106	1594	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:41
S107	7891	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S108	7	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S109	6	S108 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S110	146	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same emergency)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:45
S111	123	S110 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:45
S112	32	S97 and S111	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:48
S113	2	S112 and (without near5 (patient	US-	OR	OFF	2014/08/22

Datavant Exhibit 1002

		individual) near5 (authoriz$5 permision))	PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			16:07
S118	3	US-20060004772-$.DID. OR US-20080147554-$.DID. OR US-20110184748-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/04/18 08:27
S119	3	US-20060004772-$.DID. OR US-20080147554-$.DID. OR US-20110184748-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/04/18 08:49
S120	2	US-20090070146-$.DID. OR US-20110225007-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/04/18 09:27
S121	6	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S122	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S123	347	S122 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S124	27	S123 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S125	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S126	0	S123 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S127	0	S124 and S125	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S128	2	S122 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S129	1861	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S130	14	S125 and S129	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S131	13377	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S132	455	S131 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S133	64	S131 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S134	97	S131 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S135	72	S134 and (@pd or @ptad or @prad or @ad or @rlad)< "20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S136	2	("10825352").PN.	US-	OR	OFF	2015/04/19

Datavant Exhibit 1002

			PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			14:42
S137	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S138	70	S137 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S139	2	S138 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S140	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S141	70	S140 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S144	8730	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S145	268	S144 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S146	4439	S145 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	OFF	2015/04/19 14:42

			IBM_TDB			
S148	308	S144 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S149	502	S144 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S151	512	S144 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S152	199	S151 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S154	8127	S144 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S155	39	S144 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S157	260216	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S158	626	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S159	377	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR;	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

			FPRS; EPO; JPO; IBM_TDB			
S160	0	S159 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S161	38	S159 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S163	162742	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S164	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S165	47956	S163 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S166	47956	S163 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S168	147536	S163 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S170	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S172	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB;	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S173	0	S162 and S172	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S175	326	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S176	52	S175 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S178	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S179	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S181	55246	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S184	170	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S185	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42

S186	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S188	0	S187 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S191	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S192	586	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S194	47	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S195	0	S191 and S194	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S197	0	S191 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S198	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S199	0	S198 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S201	229	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S202	17144346	(produc$5 display) ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S204	181	S201 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S206	170	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S207	0	S206 and un$1attainab$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S208	55246	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S209	10	S206 and S208	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S217	5888	(Extending adj the adj Health adj Insurance adj Portability adj Accountability adj Act) (HIPAA)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S218	229	(((information data record)) same without near5 (patient individual) near5 authoriz$5)	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S219	229	(((information data record)) same without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S220	301	(((information data record)) same without near5 (patient individual group) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S221	56	S217 and S220	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S223	3151	705/1,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S224	21400	705/1,2,3,4,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S226	1722	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S227	8495	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S228	8	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S230	156	S224 and (access$5 near5 (patient	US-	OR	OFF	2015/04/19

Datavant Exhibit 1002

		individual group) near5 medical near5 (information data record) same emergency)	PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			14:42
S238	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S239	347	S122 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S240	27	S123 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S241	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S242	0	S123 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S243	0	S124 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S245	1861	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S247	13377	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	OFF	2015/04/19 14:44

Datavant Exhibit 1002

			IBM_TDB			
S248	455	S131 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S250	97	S131 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S253	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S254	70	S137 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S256	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S257	70	S140 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S260	8730	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S261	268	S144 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S262	4439	S145 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR;	OR	OFF	2015/04/19 14:44

			FPRS; EPO; JPO; IBM_TDB			
S264	308	S144 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S265	502	S144 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S267	512	S144 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S268	199	S151 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S270	8127	S144 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S271	39	S144 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S273	260216	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S274	626	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S275	377	(categoriz$5 group grouping grouped) near5 (patient individual)	US-PGPUB;	OR	OFF	2015/04/19 14:44

		same (medical near5 record)	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S276	0	S159 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S277	38	S159 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S279	162742	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S280	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S281	47956	S163 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S282	47956	S163 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S284	147536	S163 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S286	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44

S288	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S289	0	S162 and S172	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S291	326	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S292	52	S175 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S294	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S295	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S297	55246	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S300	170	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S301	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2015/04/19 14:44

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S302	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S304	0	S187 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S307	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S308	586	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S310	47	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S311	0	S191 and S194	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S313	0	S191 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S314	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S315	0	S198 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:44

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S317	229	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S322	4	(("20070083744") or ("20070217614") or ("20040193873")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 15:31
S325	20	US-20040143403-$.DID. OR US-20050234739-$.DID. OR US-20050261941-$.DID. OR US-20060004772-$.DID. OR US-20060020611-$.DID. OR US-20060184524-$.DID. OR US-20060229919-$.DID. OR US-20070043594-$.DID. OR US-20070219824-$.DID. OR US-20080010254-$.DID. OR US-20080120296-$.DID. OR US-20080133273-$.DID. OR US-20080147554-$.DID. OR US-20090024416-$.DID. OR US-20090070146-$.DID. OR US-20090287502-$.DID. OR US-20100162355-$.DID. OR US-20110184748-$.DID. OR US-20110225007-$.DID. OR US-20110258000-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/10/30 08:10
S326	3	("9118641").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:18
S327	369	(health$1care near5 (information data)) with ((group multiple several) near5 (individual patient))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:48
S328	21	(health$1care near5 (information data)) with ((group multiple several) near5 (token identifier) near5 (individual patient))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:50
S329	17	S328 and (@pd or @ptad or @prad or @ad or @rlad)< "20090701"	US-PGPUB; USPAT;	OR	OFF	2015/10/30 08:50

Datavant Exhibit 1002

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S330	49	((health$1care near5 (information data)) with ((group multiple several) near5 (individual patient))).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:59
S331	39	S330 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:59
S332	6	(request$2 near5 health$1care near5 (information data)) with ((group multiple several) near5 (individual patient))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:40
S333	3	S332 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:40
S334	35	(request$2 near5 health$1care near5 (information data)) with ((group multiple several))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:41
S335	20	S334 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:41
S336	1	("20020128871").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:45
S337	22	(request$2 near5 health$1care near5 (information data)) same ((group multiple several) near5 (individual patient))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:47
S338	7	S337 and (@pd or @ptad or @prad	US-	OR	OFF	2015/10/30

		or @ad or @rlad)<"20090701"	PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			15:47
S339	0	(health$1care near5 (information data)) same ((group multiple several) near5 (individual patient)) same (de$1identif$3 near5 information with token)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:58
S340	0	(health$1care near5 (information data)) same ((group multiple several) near5 (individual patient)) and (de$1identif$3 near5 information with token)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:59
S341	3	(de$1identif$3 near5 information same token)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:59
S342	7	("20090112769" | "20100287190" | "20110191767" | "20110191822" | "20130246334" | "20140053252" | "20150046192").PN.	US-PGPUB; USPAT	OR	OFF	2017/07/11 16:15
S343	20	("20040143403" | "20050234739" | "20050261941" | "20060004772" | "20060020611" | "20060184524" | "20060229919" | "20070043594" | "20070219824" | "20080010254" | "20080120296" | "20080133273" | "20080147554" | "20090024416" | "20090070146" | "20090287502" | "20100162355" | "20110184748" | "20110225007" | "20110258000").PN.	US-PGPUB; USPAT	OR	OFF	2017/07/11 16:15
S344	2	("20150295895").PN.	US-PGPUB; USPAT; USOCR; DERWENT	OR	OFF	2017/07/13 09:50
S345	10	((virtual adj private adj network) VPN) same ((convert$5 modif$5) near5 remote near5 access)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 10:55
S346	238	((virtual adj private adj network) VPN) same ((convert$5 modif$5) near5 access)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 10:57

S347	0	((virtual adj private adj network) VPN) same ((convert$5 modif$5) near5 access) same ((relay near5 system) with censor$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 10:59
S348	0	((virtual adj private adj network) VPN) same ((convert$5 modif$5) near5 access) and ((relay near5 system) with censor$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 10:59
S349	0	((virtual adj private adj network) VPN) same ((relay near5 system) with censor$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 10:59
S350	0	((virtual adj private adj network) VPN) same ((convert$5 modif$5) near5 access) and ((relay) with censor$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:00
S351	0	((virtual adj private adj network) VPN) same ((convert$5 modif$5) near5 access) and ((relay) near5 censor$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:00
S352	140	((virtual adj private adj network) VPN) and ((convert$5 modif$5) near5 remote near5 access)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:00
S353	0	S352 and censor$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:01
S354	3	(((virtual adj private adj network) VPN) and ((convert$5 modif$5) near5 remote near5 access)).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:01
S355	140	(((virtual adj private adj network) VPN) and ((convert$5 modif$5) near5 remote near5 access))	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2017/07/13 11:02

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S356	2	(((virtual adj private adj network) VPN) and ((convert$5 modif$5) near5 remote near5 access)).clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:02
S357	0	(((virtual adj private adj network) VPN) and ((convert$5) near5 remote near5 access)).clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:04
S358	2	("20120066670").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:11
S359	2	(("20150207633") or ("20140289325")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 14:33
S360	2	("20170149747").PN.	US-PGPUB; USPAT; USOCR; DERWENT	OR	OFF	2017/07/13 14:37
S361	2	(comput$5 calcul$5 determin$5) near5 (symmetric adj key) same (original near5 (name identi$5)) same nonce	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 14:42
S362	7	(comput$5 calcul$5 determin$5) near5 (key) same (original near5 (name identi$5)) same nonce	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 14:43
S363	4	(("20150040229") or ("20110107153")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/15 13:43
S364	1	("8276202").PN.	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2017/07/15 14:18

			EPO; JPO; IBM_TDB			
S365	2	("20170093586").PN.	US-PGPUB; USPAT; USOCR; DERWENT	OR	OFF	2017/07/15 14:29
S366	4	(("5099715") or ("5662188")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/16 16:35
S367	10	("9602277").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/16 19:00
S368	3	(("20100020972") or ("20090307142")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/16 19:02
S369	1	("9237146").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/11/09 16:45
S370	5	("20020188869" | "20070192140" | "20080306872" | "7900245" | "9665685").PN.	US-PGPUB; USPAT	OR	OFF	2017/11/10 06:12
S371	43926	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/11/10 06:14
S372	4544	(encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/11/10 06:14
S373	2582	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/11/10 06:15
S374	3	S371 and S372 and S373	US-	OR	OFF	2017/11/10

Datavant Exhibit 1002

			PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			06:15
S375	2	S374 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/11/10 06:15

EAST Search History (Interference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S114	10371	713/150,168.ccls. 380/ccls. 726/36.ccls.	US-PGPUB; USPAT	OR	OFF	2015/02/05 12:31
S115	0	S114 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT	OR	OFF	2015/02/05 12:31
S116	9	S114 and (without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT	OR	OFF	2015/02/05 12:32
S117	9	S116 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT	OR	OFF	2015/02/05 12:32
S318	10646	713/150,168.ccls. 380/ccls. 726/36.ccls.	US-PGPUB; USPAT	OR	OFF	2015/04/19 14:42
S319	0	S318 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT	OR	OFF	2015/04/19 14:42
S320	9	S318 and (without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT	OR	OFF	2015/04/19 14:42
S321	9	S320 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT	OR	OFF	2015/04/19 14:42
S323	13812	(H04L63/08 H04L63/08 H04L9/08).CPC.	US-PGPUB; USPAT	OR	OFF	2015/04/19 14:54
S324	0	S323 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT	OR	OFF	2015/04/19 14:56

5/ 30/ 2018 2:45:37 PM
C:\ Users\ edesrosiers\ Documents\ EAST\ Workspaces\ 14732358.wsp

1. (Currently Amended) A computer-implemented method comprising:

receiving a request message for healthcare information that characterizes a group composed of a number of individuals, wherein the request message for healthcare information is sent to an encryption server that is configured to determine if the number of individuals in the request is at least a defined minimum number of individuals, and wherein the request message includes a batch number and at least one report option;

producing, by a processor of an encryption server, a unique request token from identifying data for each individual included in the group, wherein the request tokens are encrypted before being transmitted over a network;

comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens;

producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

14. (Currently Amended) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request message for healthcare information that characterizes a group composed of a number of individuals, wherein the request message for healthcare information is sent to an encryption server that is configured to determine if the number of individuals in the request is at least a defined minimum number of individuals, and wherein the request message includes a batch number and at least one report option;

producing, by a processor of an encryption server, a unique request token from identifying data for each individual included in the group , wherein the request tokens are encrypted before being transmitted over a network;

comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens;

producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 14/732,358	Filing Date 06/05/2015	☐ To be Mailed

ENTITY: ☐ LARGE ☑ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $40 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $210 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

AMENDMENT	05/30/2018	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 22	Minus	** 22	= 0		x $50 =	0
	Independent (37 CFR 1.16(h))	* 3	Minus	*** 3	= 0		x $230 =	0
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	0

AMENDMENT		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	LIE
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	donna D smalls logan
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
14/732,358	06/05/2015	Andrew L. Paris III	25412-0002002

CONFIRMATION NO. 3202

POA ACCEPTANCE LETTER

26161
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022



Date Mailed: 05/25/2018

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 05/22/2018.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at **(571) 272-4000** or **(571) 272-4200** or **1-888-786-0101**.

/mteklemichael/

Datavant Exhibit 1002

Application Number	Application/Control No.	Applicant(s)/Patent under Reexamination	
	14/732,358	PARIS, ANDREW L.	

Document Code - DISQ	Internal Document – DO NOT MAIL

TERMINAL DISCLAIMER	☒ APPROVED	☐ DISAPPROVED
Date Filed : 22 May, 2018	This patent is subject to a Terminal Disclaimer	

Approved/Disapproved by:

CHARRISSA BROWN

Technology Center: PLRC

Telephone: (571)272-1558

Datavant Exhibit 1002

PTO/AIA/26 (04-13)
Approved for use through 04/30/2013. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) 25412-0002002

In re Application of: Andrew L. Paris III

Application No.: 14/732,358

Filed: June 5, 2015

For: De-identifying medical history information for medical underwriting

The applicant, Vigilytics LLC, owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of **prior patent** No. 9,118,641 as the term of said **prior patent** is presently shortened by any terminal disclaimer. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

expires for failure to pay a maintenance fee;
is held unenforceable;
is found invalid by a court of competent jurisdiction;
is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
has all claims canceled by a reexamination certificate;
is reissued; or
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 48,950

/Jeffrey J. Barclay, Reg. No. 48,950/ — Signature
22 May 2018 — Date

Jeffrey J. Barclay — Typed or printed name

Attorney — Title
(617) 368-2191 — Telephone Number

☐ Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

Application Number	14/732,358
Filing Date	June 5, 2015
First Named Inventor	Andrew L. Paris III
Title	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING
Art Unit	2491
Examiner Name	Evans Desrosiers
Attorney Docket Number	25412-0002002

SIGNATURE of Applicant or Patent Practitioner

Signature	/Jeffrey J. Barclay, Reg. No. 48,950/	Date (Optional)	22 May 2018
Name	Jeffrey J. Barclay	Registration Number	48,950
Title (if Applicant is a juristic entity)			
Applicant Name (if Applicant is a juristic entity)			

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If more than one applicant, use multiple forms.

☒ *Total of 1 forms are submitted.

23770783.doc

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Application Number	Filing Date

(Note: The boxes above may be left blank if information is provided on the Transmittal.)

☒ I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter, which may be an application filed after the date of this power of attorney, or identified above:

26161

OR

☐ I hereby appoint Practitioner(s) named in the attached list as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter, which may be an application filed after the date of this power of attorney, or identified above.

Please recognize or change the correspondence address for the application identified in the attached transmittal letter to:

☐ The address associated with the above-mentioned Customer Number

OR

☒ The address associated with Customer Number: **26161**

OR

Firm or Individual Name					
Address					
City		State		Zip	
Country					
Telephone		Email			

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

Vigilytics LLC

☐ Inventor or Joint Inventor (title not required below)

☐ Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)

☒ Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)

☐ Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Signature	Andrew L Paris III	Date (Optional)	
Name	Andrew L. Paris, III		
Title	President		

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

☒ *Total of 1 forms are submitted.

23770783.doc

Electronic Acknowledgement Receipt

EFS ID:	32691449
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Cathy O'Brien
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002002
Receipt Date:	22-MAY-2018
Filing Date:	05-JUN-2015
Time Stamp:	17:52:07
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	Request.pdf	43435 918c5326832eedfc0e1a5fe6d720696e4db39db	no	1

Warnings:

Datavant Exhibit 1002

Information:					
2	Application Data Sheet	ADS.pdf	69048 c5ff5c3f85d8b8e0ddf53cc08b0d6522aaac50a6	no	1
Warnings:					
Information:					
This is not an USPTO supplied ADS fillable form					
3	Assignee showing of ownership per 37 CFR 3.73	Statement.pdf	74848 6c52626c6fc6dc593aba56b88160a5b5f1540a0d	no	2
Warnings:					
Information:					
4	Terminal Disclaimer Filed	TD.pdf	59845 acf543f5b2062de1271ff3050f341e14a6bd3d8	no	1
Warnings:					
Information:					
5	Power of Attorney	POA.pdf	195377 9163554079b0aab64a90291ded0c5581ac7203ee	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	442553		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor :	Andrew L. Paris III	Art Unit :	2491
Serial No. :	14/732,358	Examiner :	Evans Desrosiers
Filed :	June 5, 2015	Conf. No. :	3202
Title :	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST TO CHANGE APPLICANT UNDER 37 CFR § 1.46(c)

Please change the applicant for the above-referenced application. Enclosed are an Application Data Sheet in accordance with 37 CFR § 1.76 that specifies the name of the new applicant in the applicant information section and a Statement under 37 CFR § 3.73(c).

Apply any charges or credits to Deposit Account No. 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 22 May 2018

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

23770766.doc

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	25412-0002002
	Application Number	14/732,358

Title of Invention	De-identifying medical history information for medical underwriting

The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant 1

If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.

☒ Assignee	☐ Legal Representative under 35 U.S.C. 117	☐ Joint Inventor
☐ Person to whom the inventor is obligated to assign.	☐ Person who shows sufficient proprietary interest	

If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:

Name of the Deceased or Legally Incapacitated Inventor :

If the Applicant is an Organization check here. ☒

Organization Name	Vigilytics LLC

Mailing Address Information:

Address 1	559 Fox Hunt Drive		
Address 2			
City	Victor	State/Province	NY
Country	US	Postal Code	14564
Phone Number		Fax Number	
Email Address			

Signature:

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.

Signature	/Jeffrey J. Barclay, Reg. No. 48,950/			Date (**MM/DD/YYYY**)	5/22/2018
First Name	Jeffrey J.	Last Name	Barclay	Registration Number	48,950

23770773.doc

PTO/AIA/96 (08-12)
Approved for use through 01/31/2013. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(c)

Applicant/Patent Owner: Andrew L. Paris III

Application No./Patent No.: 14/732,358 Filed/Issue Date: June 5, 2015

Titled: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

Vigilytics LLC, a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that, for the patent application/patent identified above, it is (choose **one** of the option 1, 2, 3 or 4 below):

1. ☒ The assignee of the entire right, title, and interest.

2. ☐ An assignee of less than the entire right, title and interest (check applicable box):

☐ The extent (by percentage) of its ownership interest is _____. Additional Statement(s) by the owners holding the balance of the interest must be submitted to account for 100% of the ownership interest.

☐ There are unspecified percentages of ownership. The other parties, including inventors, who together own the entire right, title and interest are:

Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

3. ☐ The assignee of an undivided interest in the entirety (a complete assignment from one of the joint inventors was made). The other parties, including inventors, who together own the entire right, title, and interest are:

Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

4. ☐ The recipient, via a court proceeding or the like (e.g., bankruptcy, probate), of an undivided interest in the entirety (a complete transfer of ownership interest was made). The certified document(s) showing the transfer is attached.

The interest identified in option 1, 2 or 3 above (not option 4) is evidenced by either (choose **one** of the options A or B below):

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 036263, Frame 0602, or for which a copy thereof is attached.

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Datavant Exhibit 1002

Approved for use through 01/31/2013. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(c)

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

4. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

5. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

6. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet(s).

☒ As required by 37 CFR 3.73(c)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy *(i.e.,* a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

/Jeffrey J. Barclay, Reg. No. 48,950/	22 May 2018
Signature	Date
Jeffrey J. Barclay	48,950
Printed or Typed Name	Title or Registration Number

Datavant Exhibit 1002

PTO/SB/30 (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request for Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	14/732,358
Filing Date	June 5, 2015
First Named Inventor	Andrew L. Paris III
Art Unit	2491
Examiner Name	Evans Desrosiers
Attorney Docket Number	25412-0002002

This is a Request for Continued Examination (RCE) under 37 CFR 1 .114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

   a. ☒ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

      i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

      ii. ☐ Other _____

   b. ☐ Enclosed

      i. ☐ Amendment/Reply

      ii. ☐ Affidavit(s)/ Declaration(s)

      iii. ☐ Information Disclosure Statement (IDS)

      iv. ☐ Other _____

2. Miscellaneous

   Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a

   a. ☐ period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

   b. ☐ Other _____

3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.
   The Director is hereby authorized to charge the following fees any underpayment of fees or credit any overpayments to

   a. ☒ Deposit Account No. 06-1050 .

      i ☒ RCE fee required under 37 CFR 1.17(e)

      ii ☒ Extension of time fee (37 CFR 1.136 and 1.17)

      iii ☒ Other any deficiencies

   b. ☐ Check in the amount of $ _____ enclosed

   c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Signature	/Natalie K Galley/	Date	5/2/18
Name (Print/Type)	Natalie K. Galley, Ph.D	Registration No.	L1010

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Signature			
Name (Print/Type)		Date	

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Patent Application Fee Transmittal

Application Number:	14732358
Filing Date:	05-Jun-2015
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Natalie K. Galley/Cathy O'Brien
Attorney Docket Number:	25412-0002002

Filed as Small Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension - 3 months with $300 paid	2253	1	400	400
Miscellaneous:				
RCE- 1ST REQUEST	2801	1	650	650
		Total in USD ($)		**1050**

Electronic Acknowledgement Receipt

EFS ID:	32508122
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Natalie K. Galley/Cathy O'Brien
Filer Authorized By:	Natalie K. Galley
Attorney Docket Number:	25412-0002002
Receipt Date:	02-MAY-2018
Filing Date:	05-JUN-2015
Time Stamp:	10:52:10
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$1050
RAM confirmation Number	050218INTEFSW00008548061050
Deposit Account	061050
Authorized User	Cathy O'Brien

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.21 (Miscellaneous fees and charges)

Datavant Exhibit 1002

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	RCE.pdf	116701 85c27cd8d989fe1b7c494fc5423ea6a71ba 3996	no	1

Warnings:

This is not a USPTO supplied RCE SB30 form.

Information:

2	Fee Worksheet (SB06)	fee-info.pdf	32345 52a7ed8e80c3c3df731d36d1b78666edba7 06e6c9	no	2

Warnings:

Information:

Total Files Size (in bytes):	149046

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 14/732,358	Filing Date 06/05/2015	☐ To be Mailed

ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT 05/02/2018

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 22	Minus	** 22	= 0	X $50 =	0
Independent (37 CFR 1.16(h))	* 3	Minus	***3	= 0	X $230 =	0
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	0

AMENDMENT

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

SLIE
ADRIENE SELLMAN

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Datavant Exhibit 1002

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/732,358	06/05/2015	Andrew L. Paris III	25412-0002002	3202

26161 7590 05/01/2018
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MINNESOTA 55440-1022
UNITED STATES OF AMERICA

EXAMINER	
DESROSIERS, EVANS	

ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
05/01/2018	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Datavant Exhibit 1002

Advisory Action Before the Filing of an Appeal Brief	Application No. 14/732,358	Applicant(s) Paris, Andrew L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	AIA Status No

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 20 April 2018 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

NO NOTICE OF APPEAL FILED

1. ☑ The reply was filed after a final rejection. No Notice of Appeal has been filed. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114 if this is a utility or plant application. Note that RCEs are not permitted in design applications. The reply must be filed within one of the following time periods:
   a) ☐ The period for reply expires ____ months from the mailing date of the final rejection.
   b) ☑ The period for reply expires on: (1) the mailing date of this Advisory Action; or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.
   c) ☐ A prior Advisory Action was mailed more than 3 months after the mailing date of the final rejection in response to a first after-final reply filed within 2 months of the mailing date of the final rejection. The current period for reply expires ____ months from the mailing date of *the prior Advisory Action* or SIX MONTHS from the mailing date of the final rejection, whichever is earlier.
   Examiner Note: If box 1 is checked, check either box (a), (b) or (c). ONLY CHECK BOX (b) WHEN THIS ADVISORY ACTION IS THE FIRST RESPONSE TO APPLICANTS FIRST AFTER-FINAL REPLY WHICH WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. ONLY CHECK BOX (c) IN THE LIMITED SITUATION SET FORTH UNDER BOX (c). See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) or (c) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. ☐ The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37CFR 41.37(a).

AMENDMENTS

3. ☑ The proposed amendments filed after a final rejection, but prior to the date of filing a brief, will not be entered because
   a) ☑ They raise new issues that would require further consideration and/or search (see NOTE below);
   b) ☐ They raise the issue of new matter (see NOTE below);
   c) ☑ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
   d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.
   NOTE: _____ (See 37CFR 1.116 and 41.33(a)).
4. ☐ The amendments are not in compliance with 37CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
5. ☐ Applicants reply has overcome the following rejection(s): _____
6. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
7. ☑ For purposes of appeal, the proposed amendment(s): (a) ☑ will not be entered, or (b) ☐ will be entered, and an explanation of how the new or amended claims would be rejected is provided below or appended.

AFFIDAVIT OR OTHER EVIDENCE

8. ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____
9. ☐ The affidavit or other evidence filed after final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).
10. ☐ The affidavit or other evidence filed after the date of filing the Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing of good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
11. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

12. ☐ The request for reconsideration has been considered but does NOT place the application in condition for allowance because: _____.
13. ☐ Note the attached Information *Disclosure Statement*(s). (PTO/SB/08) Paper No(s). _____
14. ☐ Other: _____.

STATUS OF CLAIMS

15. The status of the claim(s) is (or will be) as follows:
    Claim(s) allowed: _____.
    Claim(s) objected to: _____.
    Claim(s) rejected: 1-22.
    Claim(s) withdrawn from consideration: _____.

/EVANS DESROSIERS/ Primary Examiner, Art Unit 2491	

Datavant Exhibit 1002

DO NOT ENTER: /E.D/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	:	Andrew L. Paris III	Art Unit	:	2491
Serial No.	:	14/732,358	Examiner	:	Evans Desrosiers
Filed	:	June 5, 2015	Conf. No.	:	3202
Title	:	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING			

MAIL STOP AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO ACTION OF NOVEMBER 20, 2017

Please consider the following reply.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	:	Andrew L. Paris III	Art Unit	:	2491
Serial No.	:	14/732,358	Examiner	:	Evans Desrosiers
Filed	:	June 5, 2015	Conf. No.	:	3202
Title	:	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING			

MAIL STOP AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO ACTION OF NOVEMBER 20, 2017

Please consider the following reply.

List of claims (replacing prior versions).

1. (Currently Amended) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group composed of a number of ~~multiple~~ individuals, wherein the request for healthcare information is sent to an encryption server that is configured to determine if the number of individuals in the request is at least a defined minimum number of individuals, ~~the request for healthcare information containing a minimum number of individuals~~;

producing, by a processor of an encryption server, a unique request token for each individual included in the group;

comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens;

producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

2. (Original) The computer-implemented method of claim 1, wherein the provided healthcare information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

3. (Original) The computer-implemented method of claim 1, wherein receiving the request for healthcare information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

4. (Original) The computer-implemented method of claim 1, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

5. (Original) The computer-implemented method of claim 1, in which the tokens associated with healthcare data and the request tokens are similarly encrypted.

6. (Original) The computer-implemented method of claim 1, in which the healthcare data represents medical related information associated with the individuals of the group.

7. (Currently Amended) A system comprising:

a data server device for producing healthcare information that characterizes a group of a number of ~~multiple~~ individuals identified in a request for the healthcare information that characterizes the group, wherein the request for healthcare information is sent to an encryption server that is configured to determine if the number of individuals in the request is at least a defined minimum number of individuals, ~~the request for healthcare information containing a minimum number of individuals,~~ wherein a unique request token is produced for each individual included in the group, the data server is configured to compare the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens, the produced healthcare information is absent personally identifiable information and is based on a minimum number of matched tokens, the data server is also configured to provide the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

8. (Original) The system of claim 7, wherein the provided healthcare information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

9. (Original) The system of claim 7, wherein the request for healthcare information that characterizes a group of individuals includes personally identifiable information associated with the individuals of the group.

10. (Original) The system of claim 7, in which the data that identifies each individual is encrypted.

11. (Original) The system of claim 7, in which the tokens associated with the healthcare data and the request tokens are similarly encrypted.

12. (Currently Amended) The system of claim 7, in which the data server provides the requested healthcare information if the group includes at least [[a]]the minimum number of individuals.

13. (Original) The system of claim 7, in which the healthcare data represents medical related information associated with the individuals of the group.

14. (Currently Amended) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request for healthcare information that characterizes a group composed of a number of ~~multiple~~ individuals, wherein the request for healthcare information is sent to an encryption server that is configured to determine if the number of individuals in the request is at least a defined minimum number of individuals, ~~the request for healthcare information containing a minimum number of individuals~~;

producing, by a processor of an encryption server, a unique request token for each individual included in the group;

comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens;

producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

15. (Original) The computer readable storage devices of claim 14, wherein the provided healthcare information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

16. (Original) The computer readable storage devices of claim 14, wherein receiving the request for healthcare information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

17. (Original) The computer readable storage devices of claim 14, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

18. (Original) The computer readable storage devices of claim 14, in which the tokens associated with the healthcare data and the request tokens are similarly encrypted.

19. (Original) The computer readable storage devices of claim 14, in which the healthcare data represents medical related information associated with the individuals of the group.

20. (Currently Amended) The computer readable storage devices of claim 14, in which producing the requested healthcare information includes determining if the group includes at least [[a]]the minimum number of individuals.

21. (Previously Presented) The computer-implemented method of claim 1, wherein the identity of the individuals is unattainable from the unique request tokens.

22. (Previously Presented) The computer-implemented method of claim 1, wherein the unique request tokens and the tokens associated with the healthcare data are similarly encrypted.

REMARKS

The Applicant appreciates and would like to thank Examiner Evans Desrosiers for taking time out of his schedule to discuss the subject application on 14 February 2018 with Applicant's representatives, Jeffrey J. Barclay (Reg. No. 48,950) and Natalie K. Galley. Along with discussing the current action, pending independent claim 1 and the art references cited in the action were also discussed. Subsequent to that interview, the undersigned representative sent a proposal as shown in the attached amendment and briefly discussed the proposal with the Examiner on April 18th.

Claims 1-20 are pending in this application. Claims 1, 7, 12, 14, and 20 are presently amended. Support for the claim amendments can be found throughout the application as filed, for example at paragraphs 6 and 17. No new matter is added.

Rejections Under 35 U.S.C. § 103

Claims 1-22 rejected under pre-AIA 35 U.S.C. 103(a) as purportedly being unpatentable over McLaughlin (US 2009/0024416) in view of Pugh (US 2006/0229919). Amended independent claim 1 is directed to a computer-implemented method comprising receiving a request for healthcare information that characterizes a group composed of a number of individuals, wherein the request for healthcare information is sent to an encryption server that is configured to determine if the number of individuals in the request is at least a defined minimum number of individuals, producing, by a processor of an encryption server, a unique request token for each individual included in the group, comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens, producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens, and providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

McLaughlin is understood to describe a system for allowing access to patient information. Each patient has "one or more database records in which his or her medical information is stored...indexed by a unique alphanumeric identifier", where the "identifier can

be randomly generated or generated using a hash algorithm such that it does not reveal the patient's identity" (please see paragraph [0044]). McLaughlin's system "scans the patient's finger image, reads and decrypts the corresponding finger image information…and if they match, permits encrypted data to thereafter be transferred between base unit 26 and database system 12" (please see paragraph [0047]). To access the medical information McLaughlin's system requires the patient to provide biometric information, e.g., finger images, voice print, etc. (please also see paragraph [0024]). Providing biometric information to prove identity is a form of authorizing access, and the Action concedes that that McLaughlin does not disclose "providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group" and relies on Pugh to disclose the feature (see pp. 8-9 of the Action).

Pugh is understood to describe a system for creating, maintaining and selectively accessing medical histories (please see abstract). In Pugh's system, the patient has sole control over his or her medical information and the patient must grant permission to a third person such as a medical provider before any information can be accessed and viewed.

Page 9 of the Office Action points out that Pugh states that his system "can be accessed in the event of an emergency without *further* consent of the patient *as they have authorized such access when they first created their patient file*." (See also, Pugh, paragraph [0045]). As both Pugh and the Office Action state, Pugh's system explicitly requires that the patient gives access/authorization/permission when the patient's file is created. Applicant is unaware of any interpretation that the claimed "absent authorization from the group of individuals" can be reasonably interpreted as "authorized when they created their patient file".

Page 9 of the Office Action further states that "information that characterizes a group of individuals" has been interpreted as a "patient's medical history." Thus, the claimed "providing the produced healthcare information to report the characteristics of the group" has been equated to producing a single patient's medical history. Even under the broadest reasonable interpretation of claims as required by MPEP, "information to report the characteristics of the group" cannot be equated to be a single person's medical history, as the plain meaning of the word "group" means more than one individual.

Further, page 7 of the Office Action states that the feature directed to a minimum number of individuals is disclosed in McLaughlin paragraph [0030], which states in its entirety:

> "Healthcare information database system 12 is a server computer system that can include suitable non-volatile storage media such as magnetic disk arrays, processing units, working memory, database software, operating system software, network communication software, and other hardware and software elements of the types commonly included in server computer systems that manage and provide access to large databases. The database itself can be a relational database. As explained in further detail below, medical information pertaining to patients is stored in database system 12. Database system 12 can be located at any suitable site and can be remote from any or all of systems 14, 16, 18, 20, 22 and 24. Database system 12 can be operated by a third party (i.e., neither a healthcare professional nor a patient), such as contracted by a business entity that enrolls patients in its service program, as described below in further detail."

As can be seen, McLaughlin paragraph [0030] makes no reference to such a feature.

For at least these reasons, independent claim 1 is believed to be patentable over any combination of Pugh and McLaughlin. Additionally, to expedite prosecution, Applicant has amended claim 1 to include receiving a request for healthcare information that characterizes a group composed of a number of individuals, wherein the request for healthcare information is sent to an encryption server that is configured to determine if the number of individuals in the request is at least a defined minimum number of individuals. Similarly, independent claims 7 and 14 are also believed to be allowable for at least the same reasons noted above. The dependent claims respectively partake of the novelty of their parent independent claims and, as such, have not been addressed specifically herein.

Double Patenting Rejection

Claims 1-20 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-19 of U.S. Patent No. 9,118,641. To expedite prosecution, and without conceding the obviousness-type double patenting rejection, a terminal disclaimer was filed on February 14 in compliance with 37 CFR §1.321 to overcome the non-statutory double patenting rejection.

CONCLUSION

Applicant respectfully asserts that the claims under examination are in condition for allowance. Accordingly, Applicant requests the timely issuance of a Notice of Allowance. If a discussion would be helpful, the Examiner is invited to call the undersigned at the telephone number provided below.

Apply any necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 4/20/18

/Natalie K Galley/
Natalie K. Galley, Ph.D.
Reg. No. L1010

Customer Number 26161
Fish & Richardson P.C.
Telephone: +1 (617) 956-5911
Facsimile: (877) 769-7945

23717742.doc

From: Natalie Galley
Sent: Wednesday, February 28, 2018 3:27 PM
To: 'evans.desrosiers@uspto.gov'
Cc: Jeffrey Barclay; APS Outgoing
Subject: [25412-0002002] U.S. Application No. 14/732,358; Proposed Claims
Attachments: App No. 14732358 25412-0002002 proposed claim.doc

Examiner, thank you again for speaking with myself and Jeff Barclay the other day to discuss moving this case forward. Thank you as well for kindly agreeing to review the attached amendment and then calling myself or Mr. Barclay to discuss. The proposed amendment is attached. Please feel free to call us at your convenience.

Thank you again,

Natalie Galley, Ph.D., J.D. :: Associate :: Fish & Richardson P.C.
One Marina Park Drive, Boston, MA 02210-1878
617 956 5911 direct :: 617 542 5070 main :: 617 542 8906 fax

Datavant Exhibit 1002

First Named Inventor	:	Andrew L. Paris III
Serial No.	:	14/732,358
Filed	:	June 5, 2015
Title	:	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

PROPOSED CLAIM

1. (Previously Presented) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, wherein the request for healthcare information contains a minimum number of individuals and is sent to an encryption server that is configured to determine if the request contains the minimum number of individuals , ~~the request for healthcare information containing a minimum number of individuals~~;

producing, by a processor of an encryption server, a unique request token for each individual included in the group;

comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens;

producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

Electronic Patent Application Fee Transmittal

Application Number:	14732358
Filing Date:	05-Jun-2015
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Natalie K. Galley/Cathy O'Brien
Attorney Docket Number:	25412-0002002

Filed as Small Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension - 2 months with $0 paid	2252	1	300	300
Miscellaneous:				
			Total in USD ($)	**300**

Electronic Acknowledgement Receipt

EFS ID:	32396363
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Natalie K. Galley/Cathy O'Brien
Filer Authorized By:	Natalie K. Galley
Attorney Docket Number:	25412-0002002
Receipt Date:	20-APR-2018
Filing Date:	05-JUN-2015
Time Stamp:	12:21:29
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$300
RAM confirmation Number	042018INTEFSW00010599061050
Deposit Account	061050
Authorized User	Cathy O'Brien

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.21 (Miscellaneous fees and charges)

Datavant Exhibit 1002

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		Reply.pdf	769063 d2195d93a10caf9d9ace5a24c74b47c27fc3e2d3	yes	11
	Multipart Description/PDF files in .zip description				
	Document Description		**Start**	**End**	
	Response After Final Action		1	1	
	Claims		2	5	
	Applicant Arguments/Remarks Made in an Amendment		6	11	
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	30419 aa9706dfb7a1a1c7e220e2a7125709ff166d7a	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	799482		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number	Filing Date	☐ To be Mailed
14/732,358	06/05/2015	

ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT 04/20/2018

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 22	Minus	** 22	= 0	X $50 =	0
Independent (37 CFR 1.16(h))	* 3	Minus	***3	= 0	X $230 =	0
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	0

AMENDMENT

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

LIE
GAIL WOOTEN

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Datavant Exhibit 1002

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/732,358	06/05/2015	Andrew L. Paris	25412-0002002	3202

26161 7590 02/22/2018
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MINNESOTA 55440-1022

EXAMINER	
DESROSIERS, EVANS	

ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
02/22/2018	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Datavant Exhibit 1002

Applicant-Initiated Interview Summary	Application No. 14/732,358	Applicant(s) Paris, Andrew L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	AIA Status No

All participants (applicant, applicants representative, PTO personnel):

(1) EVANS DESROSIERS. (3) _____.

(2) Jeffrey Barclay. (4) _____.

Date of Interview: 14 February 2018.

Type: ☑ Telephonic ☐ Video Conference
☐ Personal [copy given to: ☐ applicant ☐ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☑ No.
If Yes, brief description: _____.

Issues Discussed ☐101 ☐112 ☐102 ☑103 ☑Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: 1.

Identification of prior art discussed: US 20090024416 A1, Pugh US 20060229919 A1.

Substance of Interview
(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

Applicant initiated the interview to discuss cited art. Claim 1 was discussed. Applicant provided the analysis of the independent claim. Further, the double patenting rejection was discuss, Applicant agreed to file a terminal disclaimer in order to overcome the rejection. Also, Applicant argued about the 103 rejection; Examiner explained how the claims have been interpreted. Finally, Applicant agreed to amend the claims in order to move the prosecution forward. Applicant will submit an official amendment. Examiner will conduct a further search and/or consideration in light of the amendment when received..

Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☐ Attachment

/EVANS DESROSIERS/ Primary Examiner, Art Unit 2491	

Datavant Exhibit 1002

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record
A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) 1.133 Interviews
Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.
All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiners responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicants correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:
- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:
1) A brief description of the nature of any exhibit shown or any demonstration conducted,-
2) an identification of the claims discussed,
3) an identification of the specific prior art discussed,
4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
5) a brief identification of the general thrust of the principal arguments presented to the examiner,
   (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
6) a general indication of any other pertinent matters discussed, and
7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicants record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiners version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, Interview Record OK on the paper recording the substance of the interview along with the date and the examiners initials.

Application Number	Application/Control No.	Applicant(s)/Patent under Reexamination
	14/732,358	PARIS, ANDREW L.

Document Code - DISQ	Internal Document – DO NOT MAIL

TERMINAL DISCLAIMER	☐ APPROVED	☒ DISAPPROVED
Date Filed : 14 February, 2018	This patent is subject to a Terminal Disclaimer	

Approved/Disapproved by:

CHARRISSA BROWN

Technology Center: PLRC

Telephone: (571)272-1558

The terminal disclaimer identifies a party who is not the applicant (only for applications filed on or after September 16, 2012; See FP 14.26.10):

For cases filed on/after 9/16/12, 37 CFR 1.321 specifies that only the applicant can disclaim, and the terminal disclaimer must specify the extent of the applicant's ownership.

Below is what needs to be done to correct the defects:

A request under 37 CFR 1.46(c) to change the applicant needs to be filed, which is (1) a request, signed by a 1.33(b) party, (2) a corrected ADS (37 CFR 1.76(c)) that identifies the "new" applicant in the applicant information, and is underlined since it is new, and (3) a 3.73(c) statement showing chain of title to the new applicant. Along with the § 1.46(c) request we need a POA that gives power to the attorney who is signing the TD, along with another copy of the TD, or a TD that is signed by the applicant.

Re-submit the TD with no additional fees required.

Datavant Exhibit 1002

PTO/AIA/26 (04-13)
Approved for use through 04/30/2013. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) 25412-0002002

In re Application of: Andrew L. Paris III

Application No.: 14/732,358

Filed: June 5, 2015

For: De-identifying medical history information for medical underwriting

The applicant, Vigilytics LLC, owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of **prior patent** No. 9,118,641 as the term of said **prior patent** is presently shortened by any terminal disclaimer. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

expires for failure to pay a maintenance fee;
is held unenforceable;
is found invalid by a court of competent jurisdiction;
is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
has all claims canceled by a reexamination certificate;
is reissued; or
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 48,950

/Jeffrey J. Barclay, Reg. No. 48,950/ — Signature
14 February 2018 — Date

Jeffrey J. Barclay — Typed or printed name

Attorney — Title
617) 368-2191 — Telephone Number

☐ Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Acknowledgement Receipt

EFS ID:	31788302
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Cathy O'Brien
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002002
Receipt Date:	14-FEB-2018
Filing Date:	05-JUN-2015
Time Stamp:	12:41:18
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Terminal Disclaimer Filed	TerminalDisclaimer.pdf	75678 109f47035d5e2f943e5ab50fec309a114e2105	no	1

Warnings:

Information:	
Total Files Size (in bytes):	75678

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/732,358	06/05/2015	Andrew L. Paris III	25412-0002002	3202

26161 7590 11/20/2017
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	

ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
11/20/2017	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Datavant Exhibit 1002

Office Action Summary	Application No. 14/732,358	Applicant(s) PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	AIA (First Inventor to File) Status No

– The MAILING DATE of this communication appears on the cover sheet with the correspondence address –

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *3* MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *10/17/2017*.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5)☒ Claim(s) *1-22* is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☒ Claim(s) *1-22* is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☒ The drawing(s) filed on *06/05/2015* is/are: a)☒ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)

2) ☒ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.

4) ☐ Other: _____.

Datavant Exhibit 1002

DETAILED ACTION

1. The present application is being examined under the pre-AIA first to invent provisions. Claims 1-22 remain for examination. Claims 1, 7 and 14 have been amended. Claims 21-22 have been added. Applicant's arguments filed on 10/17/2017 have been fully considered but they are moot in view of the new ground(s) of rejection necessitated by the amendments. Accordingly, this action has been made final.

Examiner's Note

2. Examiner has cited particular columns and line numbers in the references as applied to the claims for the convenience of the applicant. Although the specified citations are representative of the teachings of the art and are applied to the specific limitations within the individual claim, other passages and figures may apply as well. It is respectfully requested from the applicant in preparing responses, to fully consider the references in entirety as potentially teaching all or part of the claimed invention, as well as the context of the passage as taught by the prior art or disclosed by the Examiner.

Double Patenting

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims

are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 1-20 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-19 of US patent No. 9,118,641. This is a provisional double patenting rejection since the conflicting claims have not yet been patented.

Claims 1-20 recite similar limitations as claims 1-19 of US patent serial No. 9,118,641 as follows:

Instant application	US patent No. 9,118,641
Claim 1. A computer-implemented method comprising: receiving a request for healthcare information that characterizes a group composed of multiple individuals; producing, by a processor, a request token for each individual included in the group; comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens; producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.	**Claim 1.** A computer-implemented method comprising: receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information; producing, by a processor of an encryption server, tokens, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with an individual in the group, each token being associated with a corresponding token in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual; when the group includes at least a minimum number of

	individuals, producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

5. The table above shows that, although the corresponding claims are directed to different statutory categories, the US patent No. 9,118,641 implemented on a computer would render the claims in the instant application obvious.

It is clearly obvious that the (U.S. patent No. 9,118,641) substantially discloses the subject matter of claim 1 of the instant Application.

The Applicant merely broadens the scope of the instant application by deleting a few elements from the (U.S. patent No. 9,118,641).

This is a provisional obviousness-type double patenting rejection.

The claims 2-20 included in the statement of rejection but not specifically addressed in the body of the rejection have inherited the deficiencies of their parent claim and have not resolved the deficiencies. Therefore, they are rejected based on the same rationale as applied to their parent claims above.

Claim Rejections - 35 USC § 103

6. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

7. Claim 1-20 rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over McLaughlin: US 20090024416 A1in view of Pugh US 20060229919 A1.

8. **As to claim 1**, **McLaughlin** teaches a computer-implemented method comprising: receiving a request for healthcare information that characterizes a group composed of multiple individuals **(McLaughlin Pa. [0024]) [to access patient records in the database system and information stored in the token]**, wherein the request for healthcare information is sent to an encryption server **(McLaughlin Pa. [0048]) [At that time computer 28 also causes base unit 26 to encrypt and transmit the entered information to database system 12 for storage in the patient's vault] (See also, [0023] [The patient's insurance information may also be stored in the token memory. Vital medical information, such as the patient's blood type, current medications, allergies to medicines, emergency contacts, and other information that could be needed by emergency medical personnel, may also be stored in the token memory. Information stored in token memory is encrypted to safeguard against unauthorized access and tampering])**, the request for healthcare information containing a minimum number of individuals **(McLaughlin Pa. [0030]) [medical information pertaining to patients is stored in database system 12]**; producing, by a processor of an encryption server, a unique request token for each individual included in the group **(McLaughlin pa. [0287]) [a plurality of patient tokens, each token associable with an individual patient] [0023] [Each patient is issued an electronic**

token, which can be card-like, pendant-like or have any other suitably portable shape or structure]; comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens **(McLaughlin pa. [0024]) [At the healthcare professional's site or other place at which the patient receives services, an electronic base unit that can communicate with the database system via a wide-area network such as the Internet verifies the patient's identity by obtaining a biometric from the patient and comparing it to corresponding information stored in the token memory]**; producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens **(McLaughlin pa. [0024]) [healthcare professional's site or other place at which the patient receives services, an electronic base unit that can communicate with the database system via a wide-area network such as the Internet verifies the patient's identity by obtaining a biometric from the patient and comparing it to corresponding information stored in the token memory. The biometric is one known to uniquely identify a person and can be] [0044] [The vault is indexed by a unique alphanumeric identifier; no two patients' vaults have the same identifier. The identifier can be randomly generated or generated using a hash algorithm such that it does not reveal the patient's identity]**; and

It is noted that **McLaughlin** does not appear explicitly disclose providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

However, **Pugh** discloses providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group **(Pugh pa. [0044-0045]) [access to the patient's medical history... IMED database(s) may provide patent information to an emergency room that ends up saving the patient's life... IMED can be accessed in the event of an emergency without further "consent"** *(read authorization or permission)* **of the patient as they have authorized such access when they first created their patient file in the IMED system: note, "information that characterizes a group of individuals" has been interpreted as "patient's medical history"]**

McLaughlin and **Pugh** are analogous art because they are from the same field of endeavor; especially they are from the field of securing patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **McLaughlin** and **Pugh** before him or her to modify and configure the computing environment of **McLaughlin** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **Pugh.** Thus, the motivation for doing so would have been to controlling access to sensitive electronic files such as a person's medical history **(Pugh pa. [0002])**

9. **As to claim 2**, **McLaughlin** and **Pugh** teaches wherein the provided healthcare information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA) **(McLaughlin pa. [0073]) [capture and printing of a**

signature on a standardized form such as a Health Insurance Portability and Accountability Act of 1996 (HIPAA)]

10. **As to claim 3**, **McLaughlin** and **Pugh** teaches wherein receiving the request for healthcare information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group **(Pugh pa. [0017]) [The patient profile information may include the patient's name, address and telephone numbers, picture, the patient's contact information, insurance information, immunization records, birth certificate, information related to the person]**

11. **As to claim 4**, **McLaughlin** and **Pugh** teaches in which producing the requested healthcare information includes encrypting respective data that identifies each individual **(McLaughlin pa. [00287-0288]) [healthcare information entries for the patient...include biometric that to be uniquely identifiable with the patient... Information is stored in the memory of the token of an embodiment in encrypted format]**

12. **As to claim 5**, **McLaughlin** and **Pugh** teaches in which the tokens associated with healthcare data and the request tokens are similarly encrypted **(McLaughlin pa. [00288]) [tokens in encrypted format]**

13. **As to claim 6**, **McLaughlin** and **Pugh** teaches in which the healthcare data represents medical related information associated with the individuals of the group **(Pugh pa. [0042]) [IMED capabilities may include entering, storing and retrieving the detail medical history of the patient]**

14. **As to claims 7-13**, claims 7-13 recite respectively substantial the same limitations as claims 1-7, therefore, they are rejected under the same rationale.

15. **As to claims 14-19**, claims 14-19 recite respectively substantial the same limitations as claims 1-6, therefore, they are rejected under the same rationale.

16. **As to claim 20, McLaughlin** and **Pugh** teaches in which producing the requested healthcare information includes determining if the group includes at least a minimum number of individuals **(McLaughlin pa. [0222-0223]) [matching server compares the identification number to the stored number and generates a token in response to the match]**

17. **As to claim 21, McLaughlin** and **Pugh** teaches wherein the identity of the individuals is unattainable from the unique request tokens **(McLaughlin pa. [0024]) [healthcare professional's site or other place at which the patient receives services, an electronic base unit that can communicate with the database system**

via a wide-area network such as the Internet verifies the patient's identity by obtaining a biometric from the patient and comparing it to corresponding information stored in the token memory. The biometric is one known to uniquely identify a person and can be]

18. **As to claim 22, McLaughlin** and **Pugh** teaches wherein the unique request tokens and the tokens associated with the healthcare data are similarly encrypted **(McLaughlin pa. [00288]) [tokens in encrypted format]**

Response to Arguments

19. Argument 1

a. It is argued that McLaughlin is understood to describe a system for allowing access to patient information. Each patient has "one or more database records in which his or her medical information is stored.. .indexed by a unique alphanumeric identifier", where the "identifier can be randomly generated or generated using a hash algorithm such that it does not reveal the patient's identity" (please see paragraph [0044]). McLaughlin's system "scans the patient's finger image, reads and decrypts the corresponding finger image information.. .and if they match, permits encrypted data to thereafter be transferred between base unit 26 and database system 12" (please see paragraph [0047]). To access the medical information McLaughlin's system requires the

patient to provide biometric information, e.g., finger images, voice print, etc. (please also see paragraph [0024]) which is a form of authorizing access.

Although the information is stored in database records in such a way that it does not reveal the patient's identity, for the patient or another party to access the information the patient must authorize the access using his or her biometric data. In fact, this authorization from the patient (i.e., the individual associated with the information) is so integral to McLaughlin's system that McLaughlin describes a situation in which medical personnel would have to take a finger scan from an unconscious patient arriving by ambulance (please see paragraph [0052]). Thus, McLaughlin does not disclose or suggest providing produced information to report characteristics of a group of individuals absent authorization from the group of individuals, as required by independent claim 1. McLaughlin appears to suggest the opposite.

In addition, independent claim 1 is directed to a method that includes producing information that characterizes a group of individuals. McLaughlin does not teach such matter.

By contrast, McLaughlin teaches producing information for a single individual only after authenticating his or her identity by comparing biometric information of the individual (please see paragraph [0024]). Although many patients' medical information may be stored in McLaughlin's database 12, it is provided for only a single patient.

Pugh is understood to describe a system for creating, maintaining and selectively accessing medical histories (please see abstract). In Pugh's system, the patient has sole control over his or her medical information and the patient must grant permission to

a third person such as a medical provider before any information can be accessed and viewed. (*Applicant's remarks pages 2-3)*

20. Examiner's response 1.a:

In response to applicant's argument, it is respectfully submitted that the Applicant has raised a number of issues related to the McLaughlin's reference specially the way he/she understands the reference, but the Applicant has failed to show in this section of arguments which claimed limitation that McLaughlin's reference does not teach. It is clear that McLaughlin's reference disclose similar concept as the current application which is the protection of "Medical Information and identity of patients" Therefore, the Applicant's arguments are moot.

b. It is argued that Page 9 of the Office Action states that "**information that characterizes a group of individuals" has been interpreted as a "patient's medical history." T**hus, the claimed producing "information that characterizes a group of individuals" has been equated to producing a single patient's medical history. However, the MPEP states that: "[u]der a broadest reasonable interpretation, words of the claim must be given their plain meaning, unless such meaning is inconsistent with the specification. The plain meaning of a term means the ordinary and customary meaning given to the term by those of ordinary skill in the art at the time of the invention. The ordinary and customary meaning of a term may be evidenced by a variety of sources, including the words of the claims themselves, the specification, drawings, and prior art." See MPEP 2111.01.

One of ordinary skill in the art would not interpret "information that characterizes a group of individuals" to be a single person's medical history, as the plain meaning of the word "group" means more than one individual (see, e.g., American Heritage Dictionary, definition of group: 1. An assemblage of persons or objects gathered or located together; 2. A set of two or more figures that make up a unit or design, as in sculpture. 3. A number of individuals or things considered or classed together because of similarities). Further, the specification itself makes clear that the claimed "group" is more than one person. For example, the specification states that "[i]f such a minimum number of matches has not occurred in comparing the request tokens.. .action may be taken.. .until the predefined number of matches has been detected (e.g., so as not to increase the probability of one or more individuals being identified)" (please see paragraph [034]). The skilled person would therefore understand that in the context of the claim, the characteristics of the group cannot be equated to a single person's history.

Page 9 of the Office Action points out that Pugh states that his system "can be accessed in the event of an emergency without further consent of the patient as they have authorized such access when they first created their patient fde." (See Pugh, paragraph [0045]). As both Pugh and the Office Action state, Pugh's system explicitly requires that the patient gives access/authorization/permission when the patient's file is created. Applicant is unaware of any interpretation that the claimed "absent authorization from the group of individuals at any time" can be interpreted as "authorized when they created their patient file".

Applicant submits that Pugh does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals at any time, as required by independent claim 1.

For at least these reasons, independent claim 1 is believed to be patentable over any combination of Pugh and McLaughlin. Additionally, to expedite prosecution, Applicant has amended claim 1 to include receiving a request for healthcare information that characterizes a group composed of multiple individuals, wherein the request for healthcare information is sent to an encryption server, the request for healthcare information containing a minimum number of individuals, producing, by a processor of an encryption server, a unique request token for each individual included in the group. Similarly, independent claims 7 and 14 are also believed to be allowable for at least the same reasons noted above. The dependent claims respectively partake of the novelty of their parent independent claims and, as such, have not been addressed specifically herein. (*Applicant's remarks pages 2-4)*

21. Examiner's response 1.b:

In response to applicant's argument, Examiner respectfully submits that claimed limitation is to be given their broadest reasonable interpretation during prosecution, and the scope of a claim cannot be narrowed by reading disclosed limitations into the claim. See In re Morris, 127 F.3d 1048, 1054, 44 USPQ2D 1023, 1027 (Fed. Cir. 1997); In re

Zletz, 893 F.2d 319, 321, 13 USPQ2D 1320, 1322 (Fed. Cir. 1989); In re Prater, 415 F.2d 1393, 1404, 162 USPQ 541,550 (CCPA 1969). In this case, Pugh clearly discloses providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group (Pugh pa. [0044-0045]) [access to the patient's medical history... IMED database(s) may provide patent information to an emergency room that ends up saving the patient's life... IMED can be accessed in the event of an emergency without further "consent" (read authorization or permission) of the patient as they have authorized such access when they first created their patient file in the IMED system: note, "information that characterizes a group of individuals" has been interpreted as "patient's medical history"]

Conclusion

22. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to EVANS DESROSIERS whose telephone number is (571)270-5438. The examiner can normally be reached on Monday-Friday 9:00 am to 5:30 pm, EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ashokkumar Patel can be reached on (571) 272-3972. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/EVANS DESROSIERS/
Primary Examiner, Art Unit 2491

Notice of References Cited	Application/Control No. 14/732,358	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-2006/0229919 A1	10-2006	Pugh; Timothy	G06F19/322	705/3
*	B	US-2009/0024416 A1	01-2009	McLaughlin; Mark R.	G06F19/322	705/3
	C	US-				
	D	US-				
	E	US-				
	F	US-				
	G	US-				
	H	US-				
	I	US-				
	J	US-				
	K	US-				
	L	US-				
	M	US-				

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Datavant Exhibit 1002

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14732358	PARIS, ANDREW L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

CPC- SEARCHED		
Symbol	Date	Examiner
H04L63/08, H04L/0428	7/11/2017	ED
H04L63/08, H04L/0428	11/10/2017	ED

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner
380	28-30,255-283	7/11/2017	ED
713	150-154,160-167,189-193	7/11/2017	ED
380	28-30,255-283	11/10/2017	ED
713	150-154,160-167,189-193	11/10/2017	ED

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

SEARCH NOTES		
Search Notes	Date	Examiner
EAST:USPGPUB;USPAT;USOCR;FPRS;EPO;JPO;IBM_TDB	7/11/2017	ED
EAST:USPGPUB;USPAT;USOCR;FPRS;EPO;JPO;IBM_TDB	11/10/2017	ED

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner

Datavant Exhibit 1002

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5	("20020188869" | "20070192140" | "20080306872" | "7900245" | "9665685").PN.	US-PGPUB; USPAT	OR	OFF	2017/11/10 06:12
L2	43926	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/11/10 06:14
L3	4544	(encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/11/10 06:14
L4	2582	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/11/10 06:15
L5	3	2 and 3 and 4	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/11/10 06:15
L6	2	5 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/11/10 06:15
S1	3	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:15
S2	744	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2012/05/30 15:18

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S3	208	S2 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:20
S4	19	S3 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:22
S5	30884	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S6	0	S3 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S7	0	S4 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S8	2	S2 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:26
S9	1099	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:30
S10	10	S5 and S9	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:31
S11	8319	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT;	OR	OFF	2012/05/30 15:58

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S12	278	S11 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:18
S13	32	S11 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:20
S14	62	S11 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:28
S15	55	S14 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:29
S16	2	(10/825352).APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:21
S17	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:56
S18	60	S17 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:57
S19	2	S18 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:58
S20	69	group$5 near5 (patient individual)	US-	OR	OFF	2012/05/31

Datavant Exhibit 1002

		with (medical) with (data information) near5 history	PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			16:24
S21	60	S20 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S22	38	S21 and (number with (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:25
S23	8	S21 and (number near5 (patient individual) with (group set))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:27
S24	5838	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:52
S25	180	S24 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:53
S26	3325	S25 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:54
S27	6	S25 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:55
S28	222	S24 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	OFF	2012/05/31 17:04

Datavant Exhibit 1002

			IBM_TDB			
S29	346	S24 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S30	6	S24 and ((minimum maximum) near5 number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:05
S31	352	S24 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:07
S32	119	S31 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S33	112	S32 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S34	5528	S24 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S35	28	S24 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S36	26	S35 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S37	180811	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR;	OR	OFF	2012/05/31 17:16

Datavant Exhibit 1002

			FPRS; EPO; JPO; IBM_TDB			
S38	379	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S39	236	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S40	0	S39 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S41	30	S39 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S42	28	S41 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S43	109322	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:41
S44	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S45	31843	S43 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S46	31843	S43 and (minimum nera5 number near5 patient near5 group)	US-PGPUB;	OR	OFF	2012/05/31 17:42

Datavant Exhibit 1002

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S47	2	S43 and (minimum near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S48	97352	S43 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S49	6	S43 and (determin$5 near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S50	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:50
S51	138	S50 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:51
S52	30901	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S53	0	S42 and S52	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S54	3	(("7304852") or ("6041347") or ("20040205540")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:03

Datavant Exhibit 1002

S55	207	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:06
S56	36	S55 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S57	33	S56 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S58	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:47
S59	36721	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:48
S60	4	S58 and S59	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:48
S61	45185	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:50
S62	7	S58 and S61	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:51
S63	5	S62 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2013/12/06 10:52

			EPO; JPO; IBM_TDB			
S64	127	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:03
S65	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:05
S66	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S67	61	S66 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S68	0	S67 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:22
S69	33	S67 and (un$1authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:23
S70	4	S61 and S67	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:32
S71	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:28
S72	467	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT;	OR	OFF	2013/12/12 11:50

Datavant Exhibit 1002

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S73	1	S71 and S72	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:51
S74	40	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S75	0	S71 and S74	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S76	35	S74 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S77	0	S71 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S78	985	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S79	0	S78 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58
S80	5	(report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58
S81	188	((information data record)) same	US-	OR	OFF	2013/12/12

		without near5 (patient individual) near5 authoriz$5	PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			12:06
S82	10137562	(produc$5 display) ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S83	2	(produc$5 display) near5 ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S84	167	S81 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S85	2	(((information data record)) same without near5 (patient individual) near5 authoriz$5).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S86	128	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S87	0	S86 and un$1attainab$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S88	45317	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:48
S89	8	S86 and S88	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	OFF	2013/12/12 12:48

Datavant Exhibit 1002

			IBM_TDB			
S90	8	S89 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:49
S91	4	(("2007033405") or ("2003123668") or ("2001046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S92	3	(("20070033405") or ("20030123668") or ("20010046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S93	4	US-20040143403-$.DID. OR US-20060020611-$.DID. OR US-20080133273-$.DID. OR US-20090287502-$.DID.	US-PGPUB; USPAT	OR	OFF	2014/05/02 10:47
S94	2	("20030037054").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 13:40
S95	1	("6988075").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 14:30
S96	3	(("20110225007") or ("20090070146")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:01
S97	5248	(Extending adj the adj Health adj Insurance adj Portability adj Accountability adj Act) (HIPAA)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:05
S98	209	(((information data record)) same without near5 (patient individual) near5 authoriz$5)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:06

Datavant Exhibit 1002

S99	209	(((information data record)) same without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S100	264	(((information data record)) same without near5 (patient individual group) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S101	52	S97 and S100	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S102	43	S101 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:08
S103	2934	705/1,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:37
S104	19817	705/1,2,3,4,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:37
S105	3	(Internet adj medical adj information adj system (IMED)) same (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:39
S106	1594	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:41
S107	7891	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2014/08/22 15:43

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S108	7	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S109	6	S108 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S110	146	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same emergency)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:45
S111	123	S110 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:45
S112	32	S97 and S111	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:48
S113	2	S112 and (without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 16:07
S118	3	US-20060004772-$.DID. OR US-20080147554-$.DID. OR US-20110184748-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/04/18 08:27
S119	3	US-20060004772-$.DID. OR US-20080147554-$.DID. OR US-20110184748-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/04/18 08:49
S120	2	US-20090070146-$.DID. OR US-20110225007-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/04/18 09:27
S121	6	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42

S122	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S123	347	S122 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S124	27	S123 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S125	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S126	0	S123 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S127	0	S124 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S128	2	S122 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S129	1861	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S130	14	S125 and S129	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2015/04/19 14:42

			EPO; JPO; IBM_TDB			
S131	13377	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S132	455	S131 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S133	64	S131 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S134	97	S131 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S135	72	S134 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S136	2	(10/825352).APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S137	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S138	70	S137 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S139	2	S138 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S140	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S141	70	S140 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S144	8730	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S145	268	S144 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S146	4439	S145 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S148	308	S144 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S149	502	S144 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S151	512	S144 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S152	199	S151 and ("705".clas.)	US-	OR	OFF	2015/04/19

Datavant Exhibit 1002

			PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			14:42
S154	8127	S144 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S155	39	S144 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S157	260216	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S158	626	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S159	377	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S160	0	S159 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S161	38	S159 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S163	162742	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	OFF	2015/04/19 14:42

			IBM_TDB			
S164	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S165	47956	S163 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S166	47956	S163 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S168	147536	S163 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S170	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S172	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S173	0	S162 and S172	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S175	326	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S176	52	S175 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR;	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

			FPRS; EPO; JPO; IBM_TDB			
S178	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S179	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S181	55246	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S184	170	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S185	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S186	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S188	0	S187 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S191	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S192	586	(produc$5 output) near5 (information data record) same (patient individual)	US-PGPUB;	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

		near5 authoriz$5	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S194	47	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S195	0	S191 and S194	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S197	0	S191 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S198	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S199	0	S198 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S201	229	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S202	17144346	(produc$5 display) ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S204	181	S201 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42

S206	170	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S207	0	S206 and un$1attainab$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S208	55246	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S209	10	S206 and S208	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S217	5888	(Extending adj the adj Health adj Insurance adj Portability adj Accountability adj Act) (HIPAA)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S218	229	(((information data record)) same without near5 (patient individual) near5 authoriz$5)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S219	229	(((information data record)) same without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S220	301	(((information data record)) same without near5 (patient individual group) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S221	56	S217 and S220	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2015/04/19 14:42

			EPO; JPO; IBM_TDB			
S223	3151	705/1,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S224	21400	705/1,2,3,4,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S226	1722	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S227	8495	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S228	8	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S230	156	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same emergency)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S238	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S239	347	S122 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S240	27	S123 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:44

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S241	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S242	0	S123 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S243	0	S124 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S245	1861	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S247	13377	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S248	455	S131 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S250	97	S131 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S253	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S254	70	S137 and (@pd or @ptad or @prad	US-	OR	OFF	2015/04/19

		or @ad or @rlad)<"20090701"	PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			14:44
S256	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S257	70	S140 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S260	8730	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S261	268	S144 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S262	4439	S145 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S264	308	S144 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S265	502	S144 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S267	512	S144 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	OFF	2015/04/19 14:44

Datavant Exhibit 1002

			IBM_TDB			
S268	199	S151 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S270	8127	S144 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S271	39	S144 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S273	260216	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S274	626	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S275	377	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S276	0	S159 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S277	38	S159 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S279	162742	"705".clas.	US-PGPUB; USPAT; USOCR;	OR	OFF	2015/04/19 14:44

			FPRS; EPO; JPO; IBM_TDB			
S280	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S281	47956	S163 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S282	47956	S163 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S284	147536	S163 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S286	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S288	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S289	0	S162 and S172	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S291	326	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S292	52	S175 and (number quantity) near5 (patient individual) with group	US-PGPUB;	OR	OFF	2015/04/19 14:44

Datavant Exhibit 1002

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S294	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S295	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S297	55246	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S300	170	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S301	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S302	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S304	0	S187 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S307	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44

Datavant Exhibit 1002

S308	586	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S310	47	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S311	0	S191 and S194	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S313	0	S191 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S314	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S315	0	S198 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S317	229	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S322	4	(("20070083744") or ("20070217614") or ("20040193873")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 15:31
S325	20	US-20040143403-$.DID. OR US-20050234739-$.DID. OR US-20050261941-$.DID. OR US-20060004772-$.DID. OR US-20060020611-$.DID. OR US-	US-PGPUB; USPAT	OR	OFF	2015/10/30 08:10

Datavant Exhibit 1002

		20060184524-$.DID. OR US-20060229919-$.DID. OR US-20070043594-$.DID. OR US-20070219824-$.DID. OR US-20080010254-$.DID. OR US-20080120296-$.DID. OR US-20080133273-$.DID. OR US-20080147554-$.DID. OR US-20090024416-$.DID. OR US-20090070146-$.DID. OR US-20090287502-$.DID. OR US-20100162355-$.DID. OR US-20110184748-$.DID. OR US-20110225007-$.DID. OR US-20110258000-$.DID.				
S326	3	("9118641").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:18
S327	369	(health$1care near5 (information data)) with ((group multiple several) near5 (individual patient))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:48
S328	21	(health$1care near5 (information data)) with ((group multiple several) near5 (token identifier) near5 (individual patient))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:50
S329	17	S328 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:50
S330	49	((health$1care near5 (information data)) with ((group multiple several) near5 (individual patient))).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:59
S331	39	S330 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:59
S332	6	(request$2 near5 health$1care near5 (information data)) with ((group multiple several) near5 (individual patient))	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2015/10/30 15:40

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S333	3	S332 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:40
S334	35	(request$2 near5 health$1care near5 (information data)) with ((group multiple several))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:41
S335	20	S334 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:41
S336	1	("20020128871").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:45
S337	22	(request$2 near5 health$1care near5 (information data)) same ((group multiple several) near5 (individual patient))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:47
S338	7	S337 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:47
S339	0	(health$1care near5 (information data)) same ((group multiple several) near5 (individual patient)) same (de$1identif$3 near5 information with token)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:58
S340	0	(health$1care near5 (information data)) same ((group multiple several) near5 (individual patient)) and (de$1identif$3 near5 information with token)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:59
S341	3	(de$1identif$3 near5 information same token)	US-PGPUB; USPAT;	OR	OFF	2015/10/30 15:59

Datavant Exhibit 1002

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S342	7	("20090112769" | "20100287190" | "20110191767" | "20110191822" | "20130246334" | "20140053252" | "20150046192").PN.	US-PGPUB; USPAT	OR	OFF	2017/07/11 16:15
S343	20	("20040143403" | "20050234739" | "20050261941" | "20060004772" | "20060020611" | "20060184524" | "20060229919" | "20070043594" | "20070219824" | "20080010254" | "20080120296" | "20080133273" | "20080147554" | "20090024416" | "20090070146" | "20090287502" | "20100162355" | "20110184748" | "20110225007" | "20110258000").PN.	US-PGPUB; USPAT	OR	OFF	2017/07/11 16:15
S344	2	("20150295895").PN.	US-PGPUB; USPAT; USOCR; DERWENT	OR	OFF	2017/07/13 09:50
S345	10	((virtual adj private adj network) VPN) same ((convert$5 modif$5) near5 remote near5 access)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 10:55
S346	238	((virtual adj private adj network) VPN) same ((convert$5 modif$5) near5 access)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 10:57
S347	0	((virtual adj private adj network) VPN) same ((convert$5 modif$5) near5 access) same ((relay near5 system) with censor$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 10:59
S348	0	((virtual adj private adj network) VPN) same ((convert$5 modif$5) near5 access) and ((relay near5 system) with censor$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 10:59
S349	0	((virtual adj private adj network) VPN) same ((relay near5 system) with censor$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 10:59
S350	0	((virtual adj private adj network) VPN) same ((convert$5 modif$5)	US-PGPUB;	OR	OFF	2017/07/13 11:00

Datavant Exhibit 1002

		near5 access) and ((relay) with censor$3)	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S351	0	((virtual adj private adj network) VPN) same ((convert$5 modif$5) near5 access) and ((relay) near5 censor$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:00
S352	140	((virtual adj private adj network) VPN) and ((convert$5 modif$5) near5 remote near5 access)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:00
S353	0	S352 and censor$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:01
S354	3	(((virtual adj private adj network) VPN) and ((convert$5 modif$5) near5 remote near5 access)).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:01
S355	140	(((virtual adj private adj network) VPN) and ((convert$5 modif$5) near5 remote near5 access))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:02
S356	2	(((virtual adj private adj network) VPN) and ((convert$5 modif$5) near5 remote near5 access)).clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:02
S357	0	(((virtual adj private adj network) VPN) and ((convert$5) near5 remote near5 access)).clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:04
S358	2	("20120066670").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 11:11

S359	2	(("20150207633") or ("20140289325")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 14:33
S360	2	("20170149747").PN.	US-PGPUB; USPAT; USOCR; DERWENT	OR	OFF	2017/07/13 14:37
S361	2	(comput$5 calcul$5 determin$5) near5 (symmetric adj key) same (original near5 (name identi$5)) same nonce	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 14:42
S362	7	(comput$5 calcul$5 determin$5) near5 (key) same (original near5 (name identi$5)) same nonce	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/13 14:43
S363	4	(("20150040229") or ("20110107153")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/15 13:43
S364	1	("8276202").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/15 14:18
S365	2	("20170093586").PN.	US-PGPUB; USPAT; USOCR; DERWENT	OR	OFF	2017/07/15 14:29
S366	4	(("5099715") or ("5662188")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/16 16:35
S367	10	("9602277").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/07/16 19:00
S368	3	(("20100020972") or ("20090307142")).PN.	US-PGPUB;	OR	OFF	2017/07/16 19:02

Datavant Exhibit 1002

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S369	1	("9237146").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2017/11/09 16:45

11/ 10/ 2017 6:17:51 AM
C:\ Users\ edesrosiers\ Documents\ EAST\ Workspaces\ 14732358.wsp

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002002	Application No. 14/732,358
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 5, 2015	Group Art Unit 2491

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1.	2002/0188869	12/2002	Patrick			
	2.	2007/0192140	08/2007	Gropper			
	3.	2008/0306872	12/2008	Felsher			
	4.	7,900,245	03/2011	Geddes			
	5.	9,665,685	05/2017	Paris, III			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
		---	---	---				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document

Examiner Signature	Date Considered
/EVANS DESROSIERS/	11/10/2017

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.D./

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14732358	PARIS, ANDREW L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	07/11/2017	11/10/2017							
	1	✓	✓							
	2	✓	✓							
	3	✓	✓							
	4	✓	✓							
	5	✓	✓							
	6	✓	✓							
	7	✓	✓							
	8	✓	✓							
	9	✓	✓							
	10	✓	✓							
	11	✓	✓							
	12	✓	✓							
	13	✓	✓							
	14	✓	✓							
	15	✓	✓							
	16	✓	✓							
	17	✓	✓							
	18	✓	✓							
	19	✓	✓							
	20	✓	✓							
	21		✓							
	22		✓							

Datavant Exhibit 1002

Application Number	Application/Control No.	Applicant(s)/Patent under Reexamination
	14/732,358	PARIS, ANDREW L.

Document Code - DISQ	Internal Document – DO NOT MAIL

TERMINAL DISCLAIMER	☐ APPROVED	☒ DISAPPROVED
Date Filed : 17 October, 2017	This patent is subject to a Terminal Disclaimer	

Approved/Disapproved by:

CHARRISSA BROWN

Technology Center: PLRC

Telephone: (571)272-1558

The terminal disclaimer identifies a party who is not the applicant (only for applications filed on or after September 16, 2012; See FP 14.26.10):

For cases filed on/after 9/16/12, 37 CFR 1.321 specifies that only the applicant can disclaim, and the terminal disclaimer must specify the extent of the applicant's ownership.

Below is what needs to be done to correct the defects:

A request under 37 CFR 1.46(c) to change the applicant needs to be filed, which is (1) a request, signed by a 1.33(b) party, (2) a corrected ADS (37 CFR 1.76(c)) that identifies the "new" applicant in the applicant information, and is underlined since it is new, and (3) a 3.73(c) statement showing chain of title to the new applicant. Along with the § 1.46(c) request we need a POA that gives power to the attorney who is signing the TD, along with another copy of the TD, or a TD that is signed by the applicant.

Re-submit the TD with no additional fees required.

Datavant Exhibit 1002

Application Number	Application/Control No.	Applicant(s)/Patent under Reexamination
	14/732,358	PARIS, ANDREW L.

Document Code - DISQ	Internal Document – DO NOT MAIL

TERMINAL DISCLAIMER	☐ APPROVED	☒ DISAPPROVED
Date Filed : 17 October, 2017	This patent is subject to a Terminal Disclaimer	

Approved/Disapproved by:

CHARRISSA BROWN

Technology Center: PLRC

Telephone: (571)272-1558

The terminal disclaimer identifies a party who is not the applicant (only for applications filed on or after September 16, 2012; See FP 14.26.10):

For cases filed on/after 9/16/12, 37 CFR 1.321 specifies that only the applicant can disclaim, and the terminal disclaimer must specify the extent of the applicant's ownership.

Below is what needs to be done to correct the defects:

A request under 37 CFR 1.46(c) to change the applicant needs to be filed, which is (1) a request, signed by a 1.33(b) party, (2) a corrected ADS (37 CFR 1.76(c)) that identifies the "new" applicant in the applicant information, and is underlined since it is new, and (3) a 3.73(c) statement showing chain of title to the new applicant. Along with the § 1.46(c) request we need a POA that gives power to the attorney who is signing the TD, along with another copy of the TD, or a TD that is signed by the applicant.

Re-submit the TD with no additional fees required.

Datavant Exhibit 1002

PTO/AIA/26 (04-13)
Approved for use through 04/30/2013. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) 25412-0002002

In re Application of: Andrew L. Paris III

Application No.: 14/732,358

Filed: June 5, 2015

For: De-identifying medical history information for medical underwriting

The applicant, Vigilytics LLC, owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of **prior patent** No. 9,118,641 as the term of said **prior patent** is presently shortened by any terminal disclaimer. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

expires for failure to pay a maintenance fee;
is held unenforceable;
is found invalid by a court of competent jurisdiction;
is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
has all claims canceled by a reexamination certificate;
is reissued; or
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. L1010

/Natalie K Galley/ — Signature
10/17/2017 — Date

Natalie K. Galley — Typed or printed name

Law Clerk — Title
617-956-5911 — Telephone Number

☒ Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Patent Application Fee Transmittal

Application Number:	14732358
Filing Date:	05-Jun-2015
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Natalie K. Galley/Cathy O'Brien
Attorney Docket Number:	25412-0002002

Filed as Small Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
CLAIMS IN EXCESS OF 20	2202	2	40	80
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
SUBMISSION- INFORMATION DISCLOSURE STMT	2806	1	90	90
STATUTORY OR TERMINAL DISCLAIMER	2814	1	160	160
		Total in USD ($)		**330**

Electronic Acknowledgement Receipt

EFS ID:	30675064
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Natalie K. Galley/Cathy O'Brien
Filer Authorized By:	Natalie K. Galley
Attorney Docket Number:	25412-0002002
Receipt Date:	17-OCT-2017
Filing Date:	05-JUN-2015
Time Stamp:	14:59:45
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	$330
RAM confirmation Number	101817INTEFSW00001767061050
Deposit Account	061050
Authorized User	Cathy O'Brien

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.21 (Miscellaneous fees and charges)

Datavant Exhibit 1002

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		Reply.pdf	124971 ecba0c7e5825d556a326faa3a5a335780a4 5b049	yes	10
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1	
	Claims		2	5	
	Applicant Arguments/Remarks Made in an Amendment		6	10	
Warnings:					
Information:					
2		IDS.pdf	134466 16afcdd6816c8690e753492e592cbba9d0a 9b0e9	yes	2
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	1	
	Information Disclosure Statement (IDS) Form (SB08)		2	2	
Warnings:					
Information:					
3	Terminal Disclaimer Filed	TerminalDisclaimer.pdf	75301 f3e7ea2e96099917c3d797282a5b9961deb c96fe	no	1
Warnings:					
Information:					

4	Fee Worksheet (SB06)	fee-info.pdf	33799 6f0008ecbb5361d56e998bb8d9d276b041e9361	no	2
Warnings:					
Information:					
			Total Files Size (in bytes):	368537	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor :	Andrew L. Paris III	Art Unit :	2491
Serial No. :	14/732,358	Examiner :	Evans Desrosiers
Filed :	June 5, 2015	Conf. No. :	3202
Title :	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO ACTION OF JULY 17, 2017

Please consider the following reply.

List of claims (replacing prior versions).

1. (Currently Amended) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, wherein the request for healthcare information is sent to an encryption server, the request for healthcare information containing a minimum number of individuals;

producing, by a processor of an encryption server, a unique request token for each individual included in the group;

comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens;

producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

2. (Original) The computer-implemented method of claim 1, wherein the provided healthcare information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

3. (Original) The computer-implemented method of claim 1, wherein receiving the request for healthcare information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

4. (Original) The computer-implemented method of claim 1, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

5. (Original) The computer-implemented method of claim 1, in which the tokens associated with healthcare data and the request tokens are similarly encrypted.

6. (Original) The computer-implemented method of claim 1, in which the healthcare data represents medical related information associated with the individuals of the group.

7. (Currently Amended) A system comprising:

a data server device for producing healthcare information that characterizes a group of multiple individuals identified in a request for the healthcare information that characterizes the group, wherein the request for healthcare information is sent to an encryption server, the request for healthcare information containing a minimum number of individuals, wherein a unique request token is produced for each individual included in the group, the data server is configured to compare the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens, the produced healthcare information is absent personally identifiable information and is based on a minimum number of matched tokens, the data server is also configured to provide the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

8. (Original) The system of claim 7, wherein the provided healthcare information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

9. (Original) The system of claim 7, wherein the request for healthcare information that characterizes a group of individuals includes personally identifiable information associated with the individuals of the group.

10. (Original) The system of claim 7, in which the data that identifies each individual is encrypted.

11. (Original) The system of claim 7, in which the tokens associated with the healthcare data and the request tokens are similarly encrypted.

12. (Original) The system of claim 7, in which the data server provides the requested healthcare information if the group includes at least a minimum number of individuals.

13. (Original) The system of claim 7, in which the healthcare data represents medical related information associated with the individuals of the group.

14. (Currently Amended) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, wherein the request for healthcare information is sent to an encryption server, the request for healthcare information containing a minimum number of individuals;

producing, by a processor of an encryption server, a unique request token for each individual included in the group;

comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens;

producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

15. (Original) The computer readable storage devices of claim 14, wherein the provided healthcare information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

16. (Original) The computer readable storage devices of claim 14, wherein receiving the request for healthcare information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

17. (Original) The computer readable storage devices of claim 14, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

18. (Original) The computer readable storage devices of claim 14, in which the tokens associated with the healthcare data and the request tokens are similarly encrypted.

19. (Original) The computer readable storage devices of claim 14, in which the healthcare data represents medical related information associated with the individuals of the group.

20. (Original) The computer readable storage devices of claim 14, in which producing the requested healthcare information includes determining if the group includes at least a minimum number of individuals.

21. (New) The computer-implemented method of claim 1, wherein the identity of the individuals is unattainable from the unique request tokens.

22. (New) The computer-implemented method of claim 1, wherein the unique request tokens and the tokens associated with the healthcare data are similarly encrypted.

REMARKS

The Applicant appreciates and would like to thank Examiner Evans Desrosiers for taking time out of his schedule to discuss the subject application on 17 August 2017 with Applicant's representatives, Jeffrey J. Barclay (Reg. No. 48,950) and Natalie K. Galley. Along with discussing the current action, the pending claims and art references cited in the action were also discussed. Applicant's representatives proposed the changes submitted with this response, and Examiner kindly indicated that he would call Applicant's representatives when the response was filed and considered.

Claims 1-20 are pending in this application. Claims 1, 7, and 14 are presently amended, and claims 21 and 22 are new. Support for the claim amendments can be found throughout the application as filed, for example at paragraph 6, and 17. No new matter is added.

Rejections Under 35 U.S.C. § 101

Claims 7-13 are rejected under 35 U.S.C. 101 because the claimed invention is allegedly directed to non-statutory subject matter. As discussed during the interview, independent claim 7 has been amended and withdrawal of the rejection is requested.

Rejections Under 35 U.S.C. § 103

Claims 1-20 are rejected under pre-AIA 35 U.S.C. 103(a) as allegedly being unpatentable over McLaughlin, US 2009/0024416 Al in view of Pugh US 2006/0229919 A1. Amended independent claim 1 is directed to a computer-implemented method comprising receiving a request for healthcare information that characterizes a group composed of multiple individuals, wherein the request for healthcare information is sent to an encryption server, the request for healthcare information containing a minimum number of individuals, producing, by a processor of an encryption server, a unique request token for each individual included in the group, comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens, producing the healthcare information with the identity of

the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens, and providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

McLaughlin is understood to describe a system for allowing access to patient information. Each patient has "one or more database records in which his or her medical information is stored…indexed by a unique alphanumeric identifier", where the "identifier can be randomly generated or generated using a hash algorithm such that it does not reveal the patient's identity" (please see paragraph [0044]). McLaughlin's system "scans the patient's finger image, reads and decrypts the corresponding finger image information…and if they match, permits encrypted data to thereafter be transferred between base unit 26 and database system 12" (please see paragraph [0047]). To access the medical information McLaughlin's system requires the patient to provide biometric information, e.g., finger images, voice print, etc. (please also see paragraph [0024]) which is a form of authorizing access.

Although the information is stored in database records in such a way that it does not reveal the patient's identity, for the patient or another party to access the information the patient must authorize the access using his or her biometric data. In fact, this authorization from the patient (i.e., the individual associated with the information) is so integral to McLaughlin's system that McLaughlin describes a situation in which medical personnel would have to take a finger scan from an unconscious patient arriving by ambulance (please see paragraph [0052]). Thus, McLaughlin does not disclose or suggest providing produced information to report characteristics of a group of individuals absent authorization from the group of individuals, as required by independent claim 1. McLaughlin appears to suggest the opposite.

In addition, independent claim 1 is directed to a method that includes producing information that characterizes *a group* of individuals. McLaughlin does not teach such matter. By contrast, McLaughlin teaches producing information for a *single individual* only after authenticating his or her identity by comparing biometric information of the individual (please see paragraph [0024]). Although many patients' medical information may be stored in McLaughlin's database 12, it is provided for only a single patient.

Pugh is understood to describe a system for creating, maintaining and selectively accessing medical histories (please see abstract). In Pugh's system, the patient has sole control

over his or her medical information and the patient must grant permission to a third person such as a medical provider before any information can be accessed and viewed.

Page 9 of the Office Action states that "information that characterizes a group of individuals" has been interpreted as a "patient's medical history." Thus, the claimed producing "information that characterizes a group of individuals" has been equated to producing a single patient's medical history. However, the MPEP states that:

> "[u]der a broadest reasonable interpretation, words of the claim must be given their plain meaning, unless such meaning is inconsistent with the specification. The plain meaning of a term means the ordinary and customary meaning given to the term by those of ordinary skill in the art at the time of the invention. The ordinary and customary meaning of a term may be evidenced by a variety of sources, including the words of the claims themselves, the specification, drawings, and prior art." See MPEP 2111.01.

One of ordinary skill in the art would not interpret "information that characterizes a group of individuals" to be a single person's medical history, as the plain meaning of the word "group" means more than one individual (see, e.g., American Heritage Dictionary, definition of group: 1. An assemblage of persons or objects gathered or located together; 2. A set of two or more figures that make up a unit or design, as in sculpture. 3. A number of individuals or things considered or classed together because of similarities). Further, the specification itself makes clear that the claimed "group" is more than one person. For example, the specification states that "[i]f such a minimum number of matches has not occurred in comparing the request tokens…action may be taken…until the predefined number of matches has been detected (e.g., so as not to increase the probability of one or more individuals being identified)" (please see paragraph [034]). The skilled person would therefore understand that in the context of the claim, the characteristics of the group cannot be equated to a single person's history.

Page 9 of the Office Action points out that Pugh states that his system "can be accessed in the event of an emergency without *further* consent of the patient *as they have authorized such access when they first created their patient file*." (See Pugh, paragraph [0045]). As both Pugh and the Office Action state, Pugh's system explicitly requires that the patient gives access/authorization/permission when the patient's file is created. Applicant is unaware of any

interpretation that the claimed "absent authorization from the group of individuals at any time" can be interpreted as "authorized when they created their patient file".

Applicant submits that Pugh does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals at any time, as required by independent claim 1.

For at least these reasons, independent claim 1 is believed to be patentable over any combination of Pugh and McLaughlin. Additionally, to expedite prosecution, Applicant has amended claim 1 to include receiving a request for healthcare information that characterizes a group composed of multiple individuals, **wherein the request for healthcare information is sent to an encryption server, the request for healthcare information containing a minimum number of individuals**, producing, **by a processor of an encryption server, a unique** request token for each individual included in the group. Similarly, independent claims 7 and 14 are also believed to be allowable for at least the same reasons noted above. The dependent claims respectively partake of the novelty of their parent independent claims and, as such, have not been addressed specifically herein.

Double Patenting Rejections

Claims 1-20 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-19 of US Patent No. 9,118,641. To expedite prosecution, and without conceding the obviousness-type double patenting rejection, a terminal disclaimer is being filed herewith in compliance with 37 CFR §1.321 to overcome the non-statutory double patenting rejection.

CONCLUSION

Applicant respectfully asserts that the claims under examination are in condition for allowance. Accordingly, Applicant requests the timely issuance of a Notice of Allowance. If a

discussion would be helpful, the Examiner is invited to call the undersigned at the telephone number provided below.

Apply any necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 10/16/17

/Natalie K Galley/
Natalie K. Galley, Ph.D.
Reg. No. L1010

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 956-5911
Facsimile: (877) 769-7945

23672212.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor :	Andrew L. Paris III	Art Unit :	2491
Serial No. :	14/732,358	Examiner :	Evans Desrosiers
Filed :	June 5, 2015	Conf. No. :	3202
Title :	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Please consider the references listed on the enclosed Disclosure Form. The cited U.S. patents and patent application publications will be provided on request.

This statement is being filed after a first action on the merits, but before receipt of a final action or a notice of allowance. Apply the late submission fee in the amount of $90, specified by 37 CFR §1.17(p), and any other necessary charges or credits to deposit account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 10/17/17

/Natalie K Galley/
Natalie K. Galley
Reg. No. L1010

Customer Number 26161
Fish & Richardson P.C.
Telephone: +1 (617) 956-5911
Facsimile: (877) 769-7945

23682922.doc

Substitute Disclosure Form / U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002002	Application No. 14/732,358
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	Applicant Andrew L. Paris III	
	Filing Date June 5, 2015	Group Art Unit 2491

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1.	2002/0188869	12/2002	Patrick			
	2.	2007/0192140	08/2007	Gropper			
	3.	2008/0306872	12/2008	Felsher			
	4.	7,900,245	03/2011	Geddes			
	5.	9,665,685	05/2017	Paris, III			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
		---	---	---				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Datavant Exhibit 1002

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number	Filing Date	☐ To be Mailed
14/732,358	06/05/2015	

ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT 10/17/2017

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 22	Minus	** 20	= 2	X $40 =	80
Independent (37 CFR 1.16(h))	* 3	Minus	***3	= 0	X $210 =	0
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	80

AMENDMENT

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

SLIE
KIMBERLY D. WILLIAMS

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Datavant Exhibit 1002

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/732,358	06/05/2015	Andrew L. Paris III	25412-0002002	3202

26161 7590 08/23/2017
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	

ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
08/23/2017	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Datavant Exhibit 1002

Applicant-Initiated Interview Summary	Application No.	Applicant(s)	
	14/732,358	PARIS, ANDREW L.	
	Examiner	Art Unit	
	EVANS DESROSIERS	2491	

All participants (applicant, applicant's representative, PTO personnel):

(1) *EVANS DESROSIERS*.

(2) *Jeff Barclay*.

(3) *Natalie Galley*.

(4) _____.

Date of Interview: *17 August 2017*.

Type: ☒ Telephonic ☐ Video Conference
☐ Personal [copy given to: ☐ applicant ☐ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☒ No.
If Yes, brief description: _____.

Issues Discussed ☒101 ☐112 ☐102 ☒103 ☒Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: *1 and 7*.

Identification of prior art discussed: *McLaughlin: US 20090024416 A1, Pugh US 20060229919 A1.*.

Substance of Interview
(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

Applicant initiated the interview to discuss cited art, the obviousness double patenting and and the 101 rejection. More specifically how to amendment the claims to overcome McLaughlin: and Pugh. Claims 1 and were discussed. Applicant provided the analysis of the claim. Examiner explained to the Applicant how the claims have been interpreted. Applicant agreed to file a terminal disclaimer. Claimed language was provided to th eapplicant in order to overcome the 101 rejection. Also, applicant agreed to amend the claim in order to make the claimed language clearer. Examiner will conduct a further search and/or consideration in ligth of the amendment when received.

Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☐ Attachment

/EVANS DESROSIERS/ Primary Examiner, Art Unit 2491	

Datavant Exhibit 1002

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record
A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews
Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.
All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:
- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:
1) A brief description of the nature of any exhibit shown or any demonstration conducted,
2) an identification of the claims discussed,
3) an identification of the specific prior art discussed,
4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
5) a brief identification of the general thrust of the principal arguments presented to the examiner,
   (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
6) a general indication of any other pertinent matters discussed, and
7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/732,358	06/05/2015	Andrew L. Paris III	25412-0002002	3202

26161 7590 07/17/2017
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	

ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
07/17/2017	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Datavant Exhibit 1002

Office Action Summary	Application No. 14/732,358	Applicant(s) PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *06/05/2015*.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5)☒ Claim(s) *1-20* is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☒ Claim(s) *1-20* is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☒ The drawing(s) filed on *06/05/2015* is/are: a)☒ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)

2) ☒ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.

4) ☐ Other: _____.

Detailed Action

1. The present application is being examined under the pre-AIA first to invent provisions. This communication is in response to the application filed on 06/05/2015. In which Claims 1-20 are presented for examination.

Drawings

2. The applicant's drawings submitted on 06/05/2015 are acceptable for examination purposes.

Information Disclosure Statement

3. The information disclosure statement filed on 06/24/2015 and 09/20/2016 are in compliance with the provision of 37 CFR 1.97, 1.98 and MPEP § 609. It has been placed in the application file and the information referred to therein has been considered as to the merits.

Double Patenting

4. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29

USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

5. Claims 1-20 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-19 of US patent No. 9,118,641. This is a provisional double patenting rejection since the conflicting claims have not yet been patented.

6. **Claims 1-20** recite similar limitations as claims 1-19 of US patent serial No. 9,118,641 as follows:

Instant application	US patent No. 9,118,641
Claim 1. A computer-implemented method comprising: receiving a request for healthcare information that characterizes a group composed of multiple individuals; producing, by a processor, a request token for each individual included in the group; comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens; producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.	**Claim 1.** A computer-implemented method comprising: receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information; producing, by a processor of an encryption server, tokens, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with an individual in the group, each token being associated with a corresponding token in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual; when the group includes at least a minimum number of individuals, producing the requested healthcare information that characterizes

	the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

7. The table above shows that, although the corresponding claims are directed to different statutory categories, the US patent No. 9,118,641 implemented on a computer

would render the claims in the instant application obvious.

It is clearly obvious that the (U.S. patent No. 9,118,641) substantially discloses the subject matter of claim 1 of the instant Application.

The Applicant merely broadens the scope of the instant application by deleting a few elements from the (U.S. patent No. 9,118,641).

This is a provisional obviousness-type double patenting rejection.

The claims 2-20 included in the statement of rejection but not specifically addressed in the body of the rejection have inherited the deficiencies of their parent claim and have not resolved the deficiencies. Therefore, they are rejected based on the same rationale as applied to their parent claims above.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

> Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

8. Claims 7-13 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.

Claim 7 is directed to "a data server...", giving the broadest reasonable interpretation consistent with the disclosure the claim as a whole appears to be **software**, therefore, the claimed subject matter as a whole fails to fall within the definition of a process, machine, manufacture or composition of matter, patentable eligible category subject matter.

As to the dependent claims 8-13, these claims are at least rejected, directly or indirectly, on the rejected claims above. Therefore they are rejected based on the same rationale.

Claim Rejections - 35 USC § 103

9. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

10. Claim 1-20 rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over McLaughlin; US 20090024416 A1in view of Pugh US 20060229919 A1.

As to claim 1, **McLaughlin** teaches a computer-implemented method comprising: receiving a request for healthcare information that characterizes a group composed of multiple individuals **(McLaughlin Pa. [0024]) [to access patient records in the database system and information stored in the token];** producing, by a processor, a request token for each individual included in the group **(McLaughlin pa. [0287]) [a plurality of patient tokens, each token associable with an individual patient]**; comparing the request tokens to tokens associated with healthcare data that includes

de-identified information to find matching tokens **(McLaughlin pa. [0085]) [of a method 800 for controlling electronic access to healthcare records, under an embodiment. The method 800 includes generating 802 an image of a finger print of a patient, where the image is electronic. An identification number is generated 804 from the image. The identification number is compared 806 to a stored number corresponding to the patient, and the patient's identity is authenticated 808 when the comparing results in a match between the identification number and the stored number. Electronic access of remote healthcare records of the patient is controlled 810 in response to the authenticating of the patient, wherein the access of the healthcare records is initiated from the point of treatment]**;

producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens **(McLaughlin pa. [0024]) [healthcare professional's site or other place at which the patient receives services, an electronic base unit that can communicate with the database system via a wide-area network such as the Internet verifies the patient's identity by obtaining a biometric from the patient and comparing it to corresponding information stored in the token memory. The biometric is one known to uniquely identify a person and can be]**

It is noted that **McLaughlin** does not appear explicitly disclose providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

However, **Pugh** discloses providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group **(Pugh pa. [0044-0045]) [access to the patient's medical history... IMED database(s) may provide patent information to an emergency room that ends up saving the patient's life... IMED can be accessed in the event of an emergency without further "consent"** *(read authorization or permission)* **of the patient as they have authorized such access when they first created their patient file in the IMED system: note, "information that characterizes a group of individuals" has been interpreted as "patient's medical history"]**

McLaughlin and **Pugh** are analogous art because they are from the same field of endeavor; especially they are from the field of securing patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **McLaughlin** and **Pugh** before him or her to modify and configure the computing environment of **McLaughlin** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **Pugh.** Thus, the motivation for doing so would have been to controlling access to sensitive electronic files such as a person's medical history **(Pugh pa. [0002])**

11. **As to claim 2**, **McLaughlin** and **Pugh** teaches wherein the provided healthcare information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA) **(McLaughlin pa. [0073]) [capture and printing of a**

signature on a standardized form such as a Health Insurance Portability and Accountability Act of 1996 (HIPAA)]

12. **As to claim 3**, **McLaughlin** and **Pugh** teaches wherein receiving the request for healthcare information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group (**Pugh pa. [0017]) [The patient profile information may include the patient's name, address and telephone numbers, picture, the patient's contact information, insurance information, immunization records, birth certificate, information related to the person]**

13. **As to claim 4**, **McLaughlin** and **Pugh** teaches in which producing the requested healthcare information includes encrypting respective data that identifies each individual **(McLaughlin pa. [00287-0288]) [healthcare information entries for the patient...include biometric that to be uniquely identifiable with the patient... Information is stored in the memory of the token of an embodiment in encrypted format]**

14. **As to claim 5**, **McLaughlin** and **Pugh** teaches in which the tokens associated with healthcare data and the request tokens are similarly encrypted **(McLaughlin pa. [00288]) [tokens in encrypted format]**

15. **As to claim 6**, **McLaughlin** and **Pugh** teaches in which the healthcare data represents medical related information associated with the individuals of the group **(Pugh pa. [0042]) [IMED capabilities may include entering, storing and retrieving the detail medical history of the patient]**

16. **As to claims 7-13**, claims 7-13 recite respectively substantial the same limitations as claims 1-7, therefore, they are rejected under the same rationale.

17. **As to claims 14-19**, claims 14-19 recite respectively substantial the same limitations as claims 1-6, therefore, they are rejected under the same rationale.

18. **As to claim 20, McLaughlin** and **Pugh** teaches in which producing the requested healthcare information includes determining if the group includes at least a minimum number of individuals **(McLaughlin pa. [0222-0223]) [matching server compares the identification number to the stored number and generates a token in response to the match]**

Conclusion

19. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EVANS DESROSIERS whose telephone number is (571)270-5438. The examiner can normally be reached on Monday-Friday 9:00 am to 5:30 pm, EST. Examiner interviews are available via telephone, in-person, and video

conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ashokkumar Patel can be reached on (571) 272-3972. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/EVANS DESROSIERS/
Primary Examiner, Art Unit 2491

Notice of References Cited	Application/Control No. 14/732,358	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-2006/0229919 A1	10-2006	Pugh; Timothy	G06F19/322	705/3
*	B	US-2009/0024416 A1	01-2009	McLaughlin; Mark R.	G06F19/322	705/3
	C	US-				
	D	US-				
	E	US-				
	F	US-				
	G	US-				
	H	US-				
	I	US-				
	J	US-				
	K	US-				
	L	US-				
	M	US-				

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Datavant Exhibit 1002

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002002	Application No. 14/732,358
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 5, 2015	Group Art Unit

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1.	2009/0112769	04/2009	Dicks			
	2.	2010/0287190	11/2010	Anderson			
	3.	2011/0191767	08/2011	Pinsky			
	4.	2011/0191822	08/2011	Pinsky			
	5.	2013/0246334	09/2013	Ahuja			
	6.	2014/0053252	02/2014	Kelsey			
	7.	2015/0046192	02/2015	Raduchel			
	8.						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	9.							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	10.	

Examiner Signature	Date Considered
/EVANS DESROSIERS/	07/11/2017

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.D./

Datavant Exhibit 1002

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 3202

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
14/732,358	06/05/2015 **RULE**	713	2491	25412-0002002

APPLICANTS

INVENTORS
Andrew L. Paris III, Victor, NY;

** **CONTINUING DATA** **************************
This application is a CON of 12/827,745 06/30/2010 PAT 9118641
which claims benefit of 61/222,428 07/01/2009

** **FOREIGN APPLICATIONS** **************************

** **IF REQUIRED, FOREIGN FILING LICENSE GRANTED** ** ** SMALL ENTITY **
06/15/2015

Foreign Priority claimed / conditions	Met after Allowance	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
Foreign Priority claimed ☐ Yes ☑ No 35 USC 119(a-d) conditions met ☐ Yes ☑ No Verified and Acknowledged /EVANS DESROSIERS/ Examiner's Signature	☐ Met after Allowance Initials	NY	7	20	3

ADDRESS

FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022
UNITED STATES

TITLE

De-identifying medical history information for medical underwriting

FILING FEE RECEIVED	FEES	
800	FEES: Authority has been given in Paper No.__________ to charge/credit DEPOSIT ACCOUNT No.__________ for following:	☐ All Fees ☐ 1.16 Fees (Filing) ☐ 1.17 Fees (Processing Ext. of time) ☐ 1.18 Fees (Issue) ☐ Other ________ ☐ Credit

Datavant Exhibit 1002

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14732358	PARIS, ANDREW L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	07/11/2017								
	1	✓								
	2	✓								
	3	✓								
	4	✓								
	5	✓								
	6	✓								
	7	✓								
	8	✓								
	9	✓								
	10	✓								
	11	✓								
	12	✓								
	13	✓								
	14	✓								
	15	✓								
	16	✓								
	17	✓								
	18	✓								
	19	✓								
	20	✓								

Datavant Exhibit 1002

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002002	Application No. 14/732,358
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 5, 2015	Group Art Unit

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2004/0143403	07/2004	Brandon et al.			
	2	2005/0234739	10/2005	Schoenberg			
	3	2005/0261941	11/2005	Scarlat			
	4	2006/0004772	01/2006	Hagan, et al.			
	5	2006/0020611	01/2006	Gilbert et al.			
	6	2006/0184524	08/2006	Pollanz			
	7	2006/0229919	10/2006	Pugh			
	8	2007/0043594	02/2007	Lavergne			
	9	2007/0219824	09/2007	Rawlings et al.			
	10	2008/0010254	01/2008	Settimi			
	11	2008/0120296	05/2008	Kariathungal et al.			
	12	2008/0133273	06/2008	Marshall			
	13	2008/0147554	06/2008	Stevens, et al.			
	14	2009/0024416	01/2009	McLaughlin et al.			
	15	2009/0070146	03/12/2009	Haider, et al.			
	16	2009/0287502	11/2009	Roberts et al.			
	17	2010/0162355	06/2010	Zimmerman, et al.			
	18	2011/0184748	07/2011	Fierro, et al.			
	19	2011/0225007	09/15/2011	Theis			
	20	2011/0258000	10/2011	Green et al.			
	21						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	22							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form

Datavant Exhibit 1002

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.D/

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002002	Application No. 14/732,358
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Andrew L. Paris III	
		Filing Date June 5, 2015	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	23	"Group," The American Heritage Dictionary, 2014 Houghton Mifflin Harcourt, Retrieved online: https://ahdictionary.com/word/search.html?q=group (accessed 10/23/2014), 3 pages.
	24	"Health Information Privacy: Business Associates," U.S. Department of Health and Human Services, April 3, 2003, Retrieved online: http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/businessassociates.html, (accessed 10/09/2014), 2 pages.
	25	

Examiner Signature	/EVANS DESROSIERS/	Date Considered	07/11/2017

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Datavant Exhibit 1002

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.D/

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	7	("20090112769" | "20100287190" | "20110191767" | "20110191822" | "20130246334" | "20140053252" | "20150046192").PN.	US-PGPUB; USPAT	OR	OFF	2017/07/11 16:15
L2	20	("20040143403" | "20050234739" | "20050261941" | "20060004772" | "20060020611" | "20060184524" | "20060229919" | "20070043594" | "20070219824" | "20080010254" | "20080120296" | "20080133273" | "20080147554" | "20090024416" | "20090070146" | "20090287502" | "20100162355" | "20110184748" | "20110225007" | "20110258000").PN.	US-PGPUB; USPAT	OR	OFF	2017/07/11 16:15
S1	3	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:15
S2	744	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:18
S3	208	S2 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:20
S4	19	S3 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:22
S5	30884	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2012/05/30 15:25

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S6	0	S3 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S7	0	S4 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S8	2	S2 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:26
S9	1099	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:30
S10	10	S5 and S9	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:31
S11	8319	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:58
S12	278	S11 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:18
S13	32	S11 and (encrypt$5) near5 (individual patient) near5 (identity identification	US-PGPUB;	OR	OFF	2012/05/30 16:20

Datavant Exhibit 1002

		ID)	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S14	62	S11 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:28
S15	55	S14 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:29
S16	2	(10/825352).APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:21
S17	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:56
S18	60	S17 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:57
S19	2	S18 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:58
S20	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24

Datavant Exhibit 1002

S21	60	S20 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S22	38	S21 and (number with (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:25
S23	8	S21 and (number near5 (patient individual) with (group set))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:27
S24	5838	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:52
S25	180	S24 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:53
S26	3325	S25 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:54
S27	6	S25 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:55
S28	222	S24 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2012/05/31 17:04

			EPO; JPO; IBM_TDB			
S29	346	S24 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S30	6	S24 and ((minimum maximum) near5 number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:05
S31	352	S24 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:07
S32	119	S31 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S33	112	S32 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S34	5528	S24 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S35	28	S24 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S36	26	S35 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB;	OR	OFF	2012/05/31 17:12

Datavant Exhibit 1002

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S37	180811	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S38	379	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S39	236	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S40	0	S39 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S41	30	S39 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S42	28	S41 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S43	109322	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:41

S44	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S45	31843	S43 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S46	31843	S43 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S47	2	S43 and (minimum near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S48	97352	S43 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S49	6	S43 and (determin$5 near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S50	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:50
S51	138	S50 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2012/05/31 17:51

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S52	30901	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S53	0	S42 and S52	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S54	3	(("7304852") or ("6041347") or ("20040205540")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:03
S55	207	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:06
S56	36	S55 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S57	33	S56 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S58	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:47
S59	36721	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB;	OR	OFF	2013/12/06 10:48

Datavant Exhibit 1002

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S60	4	S58 and S59	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:48
S61	45185	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:50
S62	7	S58 and S61	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:51
S63	5	S62 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:52
S64	127	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:03
S65	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:05
S66	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12

Datavant Exhibit 1002

S67	61	S66 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S68	0	S67 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:22
S69	33	S67 and (un$1authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:23
S70	4	S61 and S67	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:32
S71	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:28
S72	467	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:50
S73	1	S71 and S72	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:51
S74	40	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2013/12/12 11:54

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S75	0	S71 and S74	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S76	35	S74 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S77	0	S71 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S78	985	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S79	0	S78 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58
S80	5	(report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58
S81	188	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:06
S82	10137562	(produc$5 display) ((information data record)) same without near5 (patient	US-PGPUB;	OR	OFF	2013/12/12 12:07

		individual) near5 authoriz$5	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S83	2	(produc$5 display) near5 ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S84	167	S81 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S85	2	(((information data record)) same without near5 (patient individual) near5 authoriz$5).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S86	128	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S87	0	S86 and un$1attainab$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S88	45317	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:48
S89	8	S86 and S88	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:48

Datavant Exhibit 1002

S90	8	S89 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:49
S91	4	(("2007033405") or ("2003123668") or ("2001046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S92	3	(("20070033405") or ("20030123668") or ("20010046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S93	4	US-20040143403-$.DID. OR US-20060020611-$.DID. OR US-20080133273-$.DID. OR US-20090287502-$.DID.	US-PGPUB; USPAT	OR	OFF	2014/05/02 10:47
S94	2	("20030037054").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 13:40
S95	1	("6988075").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 14:30
S96	3	(("20110225007") or ("20090070146")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:01
S97	5248	(Extending adj the adj Health adj Insurance adj Portability adj Accountability adj Act) (HIPAA)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:05
S98	209	(((information data record)) same	US-	OR	OFF	2014/08/22

		without near5 (patient individual) near5 authoriz$5)	PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			15:06
S99	209	(((information data record)) same without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S100	264	(((information data record)) same without near5 (patient individual group) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S101	52	S97 and S100	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S102	43	S101 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:08
S103	2934	705/1,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:37
S104	19817	705/1,2,3,4,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:37
S105	3	(Internet adj medical adj information adj system (IMED)) same (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	OFF	2014/08/22 15:39

			IBM_TDB			
S106	1594	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:41
S107	7891	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S108	7	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S109	6	S108 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S110	146	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same emergency)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:45
S111	123	S110 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:45
S112	32	S97 and S111	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:48
S113	2	S112 and (without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR;	OR	OFF	2014/08/22 16:07

Datavant Exhibit 1002

			FPRS; EPO; JPO; IBM_TDB			
S118	3	US-20060004772-$.DID. OR US-20080147554-$.DID. OR US-20110184748-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/04/18 08:27
S119	3	US-20060004772-$.DID. OR US-20080147554-$.DID. OR US-20110184748-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/04/18 08:49
S120	2	US-20090070146-$.DID. OR US-20110225007-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/04/18 09:27
S121	6	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S122	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S123	347	S122 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S124	27	S123 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S125	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S126	0	S123 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42

S127	0	S124 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S128	2	S122 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S129	1861	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S130	14	S125 and S129	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S131	13377	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S132	455	S131 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S133	64	S131 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S134	97	S131 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2015/04/19 14:42

			EPO; JPO; IBM_TDB			
S135	72	S134 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S136	2	(10/825352).APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S137	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S138	70	S137 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S139	2	S138 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S140	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S141	70	S140 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S144	8730	(medical record) with (categoriz$5 group grouping grouped) with (patient	US-PGPUB;	OR	OFF	2015/04/19 14:42

		individual)	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S145	268	S144 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S146	4439	S145 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S148	308	S144 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S149	502	S144 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S151	512	S144 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S152	199	S151 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S154	8127	S144 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

S155	39	S144 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S157	260216	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S158	626	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S159	377	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S160	0	S159 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S161	38	S159 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S163	162742	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S164	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S165	47956	S163 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S166	47956	S163 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S168	147536	S163 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S170	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S172	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S173	0	S162 and S172	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S175	326	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S176	52	S175 and (number quantity) near5 (patient individual) with group	US-PGPUB;	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S178	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S179	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S181	55246	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S184	170	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S185	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S186	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S188	0	S187 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

S191	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S192	586	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S194	47	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S195	0	S191 and S194	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S197	0	S191 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S198	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S199	0	S198 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S201	229	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S202	17144346	(produc$5 display) ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S204	181	S201 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S206	170	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S207	0	S206 and un$1attainab$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S208	55246	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S209	10	S206 and S208	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S217	5888	(Extending adj the adj Health adj Insurance adj Portability adj Accountability adj Act) (HIPAA)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S218	229	(((information data record)) same without near5 (patient individual)	US-PGPUB;	OR	OFF	2015/04/19 14:42

		near5 authoriz$5)	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S219	229	(((information data record)) same without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S220	301	(((information data record)) same without near5 (patient individual group) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S221	56	S217 and S220	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S223	3151	705/1,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S224	21400	705/1,2,3,4,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S226	1722	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S227	8495	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42

Datavant Exhibit 1002

S228	8	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S230	156	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same emergency)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S238	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S239	347	S122 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S240	27	S123 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S241	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S242	0	S123 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S243	0	S124 and S125	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2015/04/19 14:44

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S245	1861	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S247	13377	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S248	455	S131 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S250	97	S131 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S253	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S254	70	S137 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S256	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S257	70	S140 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB;	OR	OFF	2015/04/19 14:44

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S260	8730	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S261	268	S144 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S262	4439	S145 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S264	308	S144 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S265	502	S144 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S267	512	S144 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S268	199	S151 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44

Datavant Exhibit 1002

S270	8127	S144 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S271	39	S144 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S273	260216	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S274	626	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S275	377	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S276	0	S159 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S277	38	S159 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S279	162742	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2015/04/19 14:44

Datavant Exhibit 1002

			EPO; JPO; IBM_TDB			
S280	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S281	47956	S163 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S282	47956	S163 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S284	147536	S163 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S286	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S288	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S289	0	S162 and S172	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S291	326	(medical near5 record) same (group near5 (patient individual))	US-PGPUB;	OR	OFF	2015/04/19 14:44

Datavant Exhibit 1002

			USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			
S292	52	S175 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S294	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S295	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S297	55246	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S300	170	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S301	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S302	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44

Datavant Exhibit 1002

S304	0	S187 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S307	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S308	586	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S310	47	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S311	0	S191 and S194	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S313	0	S191 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S314	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S315	0	S198 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS;	OR	OFF	2015/04/19 14:44

			EPO; JPO; IBM_TDB			
S317	229	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S322	4	(("20070083744") or ("20070217614") or ("20040193873")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 15:31
S325	20	US-20040143403-$.DID. OR US-20050234739-$.DID. OR US-20050261941-$.DID. OR US-20060004772-$.DID. OR US-20060020611-$.DID. OR US-20060184524-$.DID. OR US-20060229919-$.DID. OR US-20070043594-$.DID. OR US-20070219824-$.DID. OR US-20080010254-$.DID. OR US-20080120296-$.DID. OR US-20080133273-$.DID. OR US-20080147554-$.DID. OR US-20090024416-$.DID. OR US-20090070146-$.DID. OR US-20090287502-$.DID. OR US-20100162355-$.DID. OR US-20110184748-$.DID. OR US-20110225007-$.DID. OR US-20110258000-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/10/30 08:10
S326	3	("9118641").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:18
S327	369	(health$1care near5 (information data)) with ((group multiple several) near5 (individual patient))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:48
S328	21	(health$1care near5 (information data)) with ((group multiple several) near5 (token identifier) near5 (individual patient))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;			

			IBM_TDB			
S329	17	S328 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:50
S330	49	((health$1care near5 (information data)) with ((group multiple several) near5 (individual patient))).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:59
S331	39	S330 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 08:59
S332	6	(request$2 near5 health$1care near5 (information data)) with ((group multiple several) near5 (individual patient))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:40
S333	3	S332 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:40
S334	35	(request$2 near5 health$1care near5 (information data)) with ((group multiple several))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:41
S335	20	S334 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:41
S336	1	("20020128871").PN.	US-PGPUB; USPAT; USOCR;	OR	OFF	2015/10/30 15:45

Datavant Exhibit 1002

			FPRS; EPO; JPO; IBM_TDB			
S337	22	(request$2 near5 health$1care near5 (information data)) same ((group multiple several) near5 (individual patient))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:47
S338	7	S337 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:47
S339	0	(health$1care near5 (information data)) same ((group multiple several) near5 (individual patient)) same (de$1identif$3 near5 information with token)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:58
S340	0	(health$1care near5 (information data)) same ((group multiple several) near5 (individual patient)) and (de$1identif$3 near5 information with token)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:59
S341	3	(de$1identif$3 near5 information same token)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/10/30 15:59

7/ 11/ 2017 4:17:28 PM
C:\ Users\ edesrosiers\ Documents\ EAST\ Workspaces\ 14732358.wsp

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14732358	PARIS, ANDREW L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

CPC- SEARCHED		
Symbol	Date	Examiner
H04L63/08, H04L/0428	7/11/2017	ED

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner
380	28-30,255-283	7/11/2017	ED
713	150-154,160-167,189-193	7/11/2017	ED

SEARCH NOTES		
Search Notes	Date	Examiner
EAST:USPGPUB;USPAT;USOCR;FPRS;EPO;JPO;IBM_TDB	7/11/2017	ED

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner

Datavant Exhibit 1002

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002002	Application No. 14/732,358
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 5, 2015	Group Art Unit

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1.	2009/0112769	04/2009	Dicks			
	2.	2010/0287190	11/2010	Anderson			
	3.	2011/0191767	08/2011	Pinsky			
	4.	2011/0191822	08/2011	Pinsky			
	5.	2013/0246334	09/2013	Ahuja			
	6.	2014/0053252	02/2014	Kelsey			
	7.	2015/0046192	02/2015	Raduchel			
	8.						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	9.							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	10.	

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Datavant Exhibit 1002

Electronic Acknowledgement Receipt

EFS ID:	26973746
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Alyssa Broderick
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002002
Receipt Date:	20-SEP-2016
Filing Date:	05-JUN-2015
Time Stamp:	10:15:15
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS.pdf	147148 099ce795c0a232fa50da99c96023a72ed99 8fedb	yes	2

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Transmittal Letter	1	1
	Information Disclosure Statement (IDS) Form (SB08)	2	2
Warnings:			
Information:			
	Total Files Size (in bytes):	147148	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor :	Andrew L. Paris III	Art Unit :	Unknown
Serial No. :	14/732,358	Examiner :	Unknown
Filed :	June 5, 2015	Conf. No. :	3202
Title :	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Please consider the references listed on the enclosed PTO-SB-08 or Disclosure Form. Cited U.S. patents and patent application publications will be provided on request.

This statement is being filed within three months of the filing date of the application or before the receipt of a first action on the merits.

Apply any necessary charges or credits to deposit account 06-1050, referencing the above attorney docket number.

Please contact the undersigned if there are any questions regarding this Statement.

Respectfully submitted,

Date: 19 September 2016

/Jeffrey J. Barclay, Reg. No. 48,950/

Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 956-5911
Facsimile: (877) 769-7945

23557314.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	: Andrew L. Paris III	Art Unit	: Unknown
Serial No.	: 14/732,358	Examiner	: Unknown
Filed	: June 5, 2015	Conf. No.	: 3202
Title	: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATUS INQUIRY

Applicant respectfully inquires as to the status of the above application. The application was filed on June 5, 2015 and its last known status was "Docketed New Case – Ready for Examination".

Please apply any necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 16 August 2019

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

23555146.doc

Electronic Acknowledgement Receipt

EFS ID:	26651619
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Alyssa Broderick
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002002
Receipt Date:	16-AUG-2016
Filing Date:	05-JUN-2015
Time Stamp:	12:02:39
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for status of Application	Status.pdf	43725 c0ce59ccea5557829601f500d763c117739...6865	no	1

Warnings:

Datavant Exhibit 1002

Information:	
Total Files Size (in bytes):	43725

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
14/732,358	06/05/2015	Andrew L. Paris III	25412-0002002

CONFIRMATION NO. 3202

POA ACCEPTANCE LETTER

26161
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

OC000000077964543

Date Mailed: 10/13/2015

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 10/02/2015.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at **(571) 272-4000** or **(571) 272-4200** or **1-888-786-0101**.

/hachristian/

Datavant Exhibit 1002

PTO/AIA/80 (07-12)
Approved for use through 11/30/2014. OMB 0651-0035
U.S. Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(c).

I hereby appoint:

■ Practitioners associated with Customer Number: 26161

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

As attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignments documents attached to this form in accordance with 37 CFR 3.73(c).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(c) to:

■ The address associated with Customer Number: 26161

OR

☐

Firm or Individual Name			
Address			
City		State	Zip
Country			
Telephone		Email	

Assignee Name and Address: Vigilytics LLC
559 Fox Hunt Drive
Victor, New York 14564

A copy of this form, together with a statement under 37 CFR 3.73(c) (Form PTO/AIA/96 or equivalent) is required to be Filed in each application in which this form is used. The statement under 37 CFR 3.73(c) may be completed by one of The practitioners appointed in this form, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature	Andrew L Paris III	Date	01/22/2014
Name	Andrew L. Paris, III	Telephone	585-924-4667
Title	President		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Acknowledgement Receipt

EFS ID:	23679273
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Natalie K. Galley/Alyssa Broderick
Filer Authorized By:	Natalie K. Galley
Attorney Docket Number:	25412-0002002
Receipt Date:	02-OCT-2015
Filing Date:	05-JUN-2015
Time Stamp:	15:44:11
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		POA.pdf	121957 39c48e4093c0bcf8f4f46b47918d875dda0d53e	yes	2

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Transmittal Letter	1	1
	Power of Attorney	2	2
Warnings:			
Information:			
	Total Files Size (in bytes):	121957	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

Application Number	14/732,358
Filing Date	June 5, 2015
First Named Inventor	Andrew L. Paris III
Title	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING
Art Unit	
Examiner Name	
Attorney Docket Number	25412-0002002

SIGNATURE of Applicant or Patent Practitioner

Signature	/Natalie K Galley/	Date (Optional)	10/2/15
Name	Natalie K. Galley, Ph.D	Registration Number	L1010
Title (if Applicant is a juristic entity)			
Applicant Name (if Applicant is a juristic entity)			

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ *Total of _____ forms are submitted.

23424196.doc

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

As the below named inventor, I hereby declare that:

This declaration is directed to:

[ ] The attached application, or

[X] United States application or PCT international application number 14/732,358

filed on June 5, 2015.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Andrew L. Paris III Date (Optional): _____

Signature: Andrew L Paris III

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet Inc.
www.FormsWorkflow.com

Datavant Exhibit 1002

Electronic Acknowledgement Receipt

EFS ID:	23046045
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Alyssa Broderick
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002002
Receipt Date:	28-JUL-2015
Filing Date:	05-JUN-2015
Time Stamp:	15:08:33
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Oath or Declaration filed	Declaration.pdf	113780 612bcf5ef6be191cc60b3565897f9cd4c874 9984	no	1

Warnings:	
Information:	

Datavant Exhibit 1002

Total Files Size (in bytes):	113780

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002002	Application No. 14/732,358
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Andrew L. Paris III	
		Filing Date June 5, 2015	Group Art Unit

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2004/0143403	07/2004	Brandon et al.			
	2	2005/0234739	10/2005	Schoenberg			
	3	2005/0261941	11/2005	Scarlat			
	4	2006/0004772	01/2006	Hagan, et al.			
	5	2006/0020611	01/2006	Gilbert et al.			
	6	2006/0184524	08/2006	Pollanz			
	7	2006/0229919	10/2006	Pugh			
	8	2007/0043594	02/2007	Lavergne			
	9	2007/0219824	09/2007	Rawlings et al.			
	10	2008/0010254	01/2008	Settimi			
	11	2008/0120296	05/2008	Kariathungal et al.			
	12	2008/0133273	06/2008	Marshall			
	13	2008/0147554	06/2008	Stevens, et al.			
	14	2009/0024416	01/2009	McLaughlin et al.			
	15	2009/0070146	03/12/2009	Haider, et al.			
	16	2009/0287502	11/2009	Roberts et al.			
	17	2010/0162355	06/2010	Zimmerman, et al.			
	18	2011/0184748	07/2011	Fierro, et al.			
	19	2011/0225007	09/15/2011	Theis			
	20	2011/0258000	10/2011	Green et al.			
	21						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	22							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Datavant Exhibit 1002

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002002	Application No. 14/732,358
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Andrew L. Paris III	
		Filing Date June 5, 2015	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	23	"Group," The American Heritage Dictionary, 2014 Houghton Mifflin Harcourt, Retrieved online: https://ahdictionary.com/word/search.html?q=group (accessed 10/23/2014), 3 pages.
	24	"Health Information Privacy: Business Associates," U.S. Department of Health and Human Services, April 3, 2003, Retrieved online: http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/businessassociates.html, (accessed 10/09/2014), 2 pages.
	25	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Datavant Exhibit 1002

Electronic Acknowledgement Receipt

EFS ID:	22722256
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying medical history information for medical underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Alyssa Broderick
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002002
Receipt Date:	24-JUN-2015
Filing Date:	05-JUN-2015
Time Stamp:	10:58:48
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		ids.pdf	135123 a4a75060f1288748b1b127af2812d469ef2 6a8c	yes	3

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Transmittal Letter	1	1
	Information Disclosure Statement (IDS) Form (SB08)	2	3

Warnings:					
Information:					
2	Non Patent Literature	art1.pdf	480100 a5560dba3afed9268bc880f35d28c8af76c1a1e4	no	3
Warnings:					
Information:					
3	Non Patent Literature	art2.pdf	106997 26eeb61b57a7f32031 5a4ac49470fc80a9f18ac5	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	722220		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	:	Andrew L. Paris III	Art Unit	:	Unknown
Serial No.	:	14/732,358	Examiner	:	Unknown
Filed	:	June 5, 2015	Conf. No.	:	3202
Title	:	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING			

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Please consider the references listed on the enclosed PTO-SB-08 or Disclosure Form. Foreign patent documents and non-patent literature are enclosed; cited U.S. patents and patent application publications will be provided on request. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

This statement is being filed within three months of the filing date of the application or before the receipt of a first action on the merits.

Apply any necessary charges or credits to deposit account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 24 June 2015

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 956-5911
Facsimile: (877) 769-7945

23401798.doc

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
14/732,358	06/05/2015	Andrew L. Paris III	25412-0002002

CONFIRMATION NO. 3202

26161
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

INFORMAL NOTICE

OC000000075752065

Date Mailed: 06/18/2015

INFORMATIONAL NOTICE TO APPLICANT

Applicant is notified that the above-identified application contains the deficiencies noted below. No period for reply is set forth in this notice for correction of these deficiencies. However, if a deficiency relates to the inventor's oath or declaration, the applicant must file an oath or declaration in compliance with 37 CFR 1.63, or a substitute statement in compliance with 37 CFR 1.64, executed by or with respect to each actual inventor no later than the expiration of the time period set in the "Notice of Allowability" to avoid abandonment. See 37 CFR 1.53(f).

The item(s) indicated below are also required and should be submitted with any reply to this notice to avoid further processing delays.

- A properly executed inventor's oath or declaration has not been received for the following inventor(s):
  Andrew L. Paris III

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at **(571) 272-4000** or **(571) 272-4200** or **1-888-786-0101**.

/tlc/

Datavant Exhibit 1002

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number: 14/732,358

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY FEE($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	70		N/A	
SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A	N/A	300		N/A	
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	360		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	20 minus 20 =	*	x 40 =	0.00	OR		
INDEPENDENT CLAIMS (37 CFR 1.16(h))	3 minus 3 =	*	x 210 =	0.00			
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			0.00			
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				0.00			
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	730		TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT A	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE($)	ADDITIONAL FEE($)		RATE($)	ADDITIONAL FEE($)
AMENDMENT B	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
PO Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
14/732,358	06/05/2015	2855	800	25412-0002002	20	3

CONFIRMATION NO. 3202

FILING RECEIPT

26161
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

OC000000075752084

Date Mailed: 06/18/2015

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)
Andrew L. Paris III, Victor, NY;

Applicant(s)
Andrew L. Paris III, Victor, NY;

Assignment For Published Patent Application
VIGILYTICS LLC, Victor, NY

Power of Attorney: None

Domestic Priority data as claimed by applicant
This application is a CON of 12/827,745 06/30/2010
which claims benefit of 61/222,428 07/01/2009

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

If Required, Foreign Filing License Granted: 06/15/2015

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 14/732,358**

Projected Publication Date: Request for Non-Publication Acknowledged

Non-Publication Request: Yes

Early Publication Request: No

** **SMALL ENTITY** **

Datavant Exhibit 1002

Title

De-identifying medical history information for medical underwriting

Preliminary Class

073

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

Datavant Exhibit 1002

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

Datavant Exhibit 1002

FISH.

Street Address
Fish & Richardson P.C.
One Marina Park Drive
Boston, MA 02210-1878

Mail Address
P.O. Box 1022
Minneapolis, MN 55440-1022

617 542 5070 main
877 769 7945 fax

June 5, 2015

Attorney Docket No.: 25412-0002002/

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Presented for filing is a new continuation patent application of:

Inventor(s): ANDREW L. PARIS III

Title: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

Enclosed are the following papers, including those required to receive a filing date under 37 C.F.R. § 1.53(b):

	Pages
Specification	16
Claims	3
Abstract	1
Drawing(s)	7

Enclosures:

— Application Data Sheet, 7 pages.

— Nonpublication Request Under 35 U.S.C. 122(b)(2)(B)(i), 1 page.

This application is a continuation application and claim priority under 35 USC §120 to U.S. Application Serial No. 12/827,745, filed on June 30, 2010, which claims benefit to U.S. Provisional Application Serial No. 61/222,428, filed on July 1, 2009, the entire contents of both which are hereby incorporated by reference.

Applicant claims small entity status. See 37 CFR 1.27.

Datavant Exhibit 1002

FISH.

Commissioner for Patents
June 5, 2015

Basic Filing Fee			$70
Search Fee			$300
Examination Fee			$360
Total Claims 20	over 20	**0 x $40**	$0
Independent Claims 3	over 3	**0 x $210**	$0
Fee for Multiple Dependent claims			$0
Application size fee for each 50 pages over 100 Total Sheets: 7x .75 - 100/50 = 0x			$0
Surcharge - Late filing fee, search fee, examination fee or oath or declaration			$70
Total Filing fee			$800

The filing fee in the amount of $800 is being paid concurrently herewith on the Electronic Filing System (EFS) by way of Deposit Account authorization. Please apply all charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 25412-0002002.

If this application is found to be incomplete, or if a telephone conference would otherwise be helpful, please call the undersigned at (617) 956-5911.

Please direct all correspondence to the following:

26161
PTO Customer Number

Respectfully submitted,

/Jeffrey J. Barclay, Reg. No. 48,950/

Jeffrey J. Barclay

Reg. No. 48,950
23400884.doc

De-identifying Medical History Information for Medical Underwriting

CLAIM OF PRIORITY

[001] This application is a continuation application and claim priority under 35 USC §120 to U.S. Application Serial No. 12/827,745, filed on June 30, 2010, which claims benefit to U.S. Provisional Application Serial No. 61/222,428, filed on July 1, 2009, the entire contents of both which are hereby incorporated by reference.

BACKGROUND

[002] The present disclosure relates to processing and transmitting personal data, the dissemination of which is restricted by federal law.

[003] Due to federal privacy laws, companies that offer health insurance to small and midsize groups (containing 10 – 1000 individuals) are often unable to obtain the health history data they need to estimate the risk of insuring such groups commonly referred to as "experience rating". This frequently leads to less than optimal pricing for the companies, the groups, or both. Healthcare providers such as pharmacies and hospitals generate private healthcare data about patients, including medical and prescription drug history, and administrative healthcare claims data. Data that associates patient identity with health information is known as protected health information (PHI). Healthcare providers can store protected health information in electronic databases for future use in patient care and insurance claims processing. Insurance companies have developed techniques to estimate their risk from insuring a group of people by processing the protected health information about the group. Federal privacy laws, however, prevent the insurance companies from obtaining protected health information without individual authorizations from the each person in the group.

SUMMARY

[004] The systems and techniques described here relate to de-identifying medical history information.

[005] In one aspect, a computer-implemented method includes producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals. The identity of the individuals is unattainable from the produced information. The method also includes providing the produced information to report the characteristics of the group.

[006] Implementations may include any of all of the following features. Producing information that characterizes the group may include producing a request token for each individual included in the group. Producing such a request token for each individual may include encrypting respective data that identifies each individual. Producing information that characterizes the group may include comparing the request tokens to tokens associated with the information to be produced. The tokens associated with the information to be produced and the request tokens may be similarly encrypted. Producing information that characterizes the group may includes determining if the comparison provides at least a minimum number of matches. Producing information that characterizes the group may include requesting a predefined portion of the information. Additionally, producing information that characterizes the group may include determining if the group includes at least a minimum number of individuals. The private data may represent medical related information associated with the individuals of the group.

[007] In another aspect a system includes an encryption server for producing a request token of each individual included in a group identified in a request for information that characterizes the group. The system may also include a data server for producing the information that characterizes the group from a set of private data representing characteristics of the individuals. The identity of the individuals is unattainable from the produced information. The data server is also configured to provide the produced information to report the characteristics of the group.

[008] Implementations may include any of all of the following features. The data server may provide a request token for each individual included in the group to produce the information that characterizes the group. The request token for each individual may

Datavant Exhibit 1002

represent encrypted data that identifies the corresponding individual. The data server may be configured to compare the request tokens to tokens associated with the information to be produced. The tokens associated with the information to be produced and the request tokens may be similarly encrypted. The data server may be configured to determine if the comparison provides at least a minimum number of matches. The request may represent a predefined portion of information to use for producing the information that characterizes the group. The encryption server may be configured to determine if the group includes at least a minimum number of individuals. The private data may represent medical related information associated with the individuals of the group.

[009] In another aspect, one or more computer readable media storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations that include producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals. The identity of the individuals is unattainable from the produced information. The operations also include providing the produced information to report the characteristics of the group.

[010] Implementations may include any of all of the following features. Producing information that characterizes the group may include producing a request token for each individual included in the group. Producing such a request token for each individual may include encrypting respective data that identifies each individual. Producing information that characterizes the group may include comparing the request tokens to tokens associated with the information to be produced. The tokens associated with the information to be produced and the request tokens may be similarly encrypted. Producing information that characterizes the group may includes determining if the comparison provides at least a minimum number of matches. Producing information that characterizes the group may include requesting a predefined portion of the information. Additionally, producing information that characterizes the group may include determining if the group includes at least a minimum number of individuals. The private

Datavant Exhibit 1002

data may represent medical related information associated with the individuals of the group.

[011] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 illustrates exemplary circumstances in which protected health information is stored by healthcare providers, claims clearing houses, and other source sites, and requested by an insurer.

FIG. 2 illustrates an exemplary method and system that enables an insurer to obtain medical information about a group of people without violating the privacy of persons in the group.

FIG. 3 illustrates an exemplary system incorporating an encryption server and a de-identified data server to enable a user who is not permitted to obtain the private data of a group of people to instead obtain a report that characterizes the group as a whole.

FIG. 4 illustrates an exemplary message requesting de-identified data about a group of people.

FIG. 5 is a flowchart that represents exemplary operations of a token generator.

FIG. 6 is a flowchart that represents exemplary operations of a token matcher.

FIG. 7 represents a computer system and related components.

Like reference symbols in the various drawings indicate like elements.

Datavant Exhibit 1002

DETAILED DESCRIPTION

[012] Referring to FIG. 1, when a doctor treats Jack 102 for high blood pressure, a surgeon removes Jack's gallstones, and a pharmacist fills Jack's prescription for insulin, Jack leaves a trail of electronic records 104 with healthcare professionals (e.g., healthcare profession 106), in their offices (e.g., doctor's office, nurse's station, etc.), in healthcare facilities (e.g., a hospital 108, a pharmacy 110, a nursing home, etc.) and the like. The electronic records 104 contain medical data 112 about Jack, for example his illnesses 114 and treatments 116. Each piece of medical data 112 is associated with personally identifiable information 118 that identifies Jack and distinguishes him from all other patients, such as his first name 120, last name 122, date of birth 124, gender 126, and zip code 128. Together, the pieces of medical data 112 and the personally identifiable information 118 make up Jack's protected health information (PHI) 130.

[013] Each of Jack's healthcare providers may submit health insurance claims 105 containing PHI 130, as well as additional PHI 130, to a claims clearing house 137. The claims clearing house 137 may store the PHI 130 of many patients 134, including Jack, in a PHI database 136. A de-identifier 142 can process the PHI 136 to generate irreversibly de-identified data 140 by removing all personally identifiable information 118 or otherwise transforming the PHI 130 so that it cannot be associated with a particular person. A claims warehouse 139 stores de-identified data 140 about many patients 134. Claims clearing houses 137 and claims warehouses 139 are optimized for retrieving and providing PHI 136 and de-identified data 140 for use in further processing, but health care providers such as healthcare professional 106 and pharmacies 110 may also serve as source sites 138 for de-identified data in a distributed system.

[014] By searching for Jack's personally identifiable information 118 in its electronic records 104, the pharmacy 110 is able to look up the various drugs in Jack's PHI 130 and, for example, check for bad interactions among them. Jack does not object to this use of his PHI 130 because it improves the quality of his healthcare. On the other hand, Jack would object to the pharmacy 110 giving his PHI 130 to third parties without

Datavant Exhibit 1002

his permission because that would disclose personal, private information about him that Jack's potential employers, for example, might use to discriminate against him.

[015] Federal laws, such as the Health Insurance Portability and Accountability Act (HIPAA), protect Jack by prohibiting the source sites 138 possessing Jack's PHI 130 from releasing it to third parties without Jack's permission. Under HIPAA, the source sites 138 can release only irreversibly de-identified data 140 without Jack's permission.

[016] A health insurer 150, for example, may be interested in the medical history information contained in Jack's PHI 130. Jack's employer 152 may like to buy a group health insurance policy for the group 154 made up of Jack 102 and his coworkers 156. If the group 154 is too small, the insurance company 150 will not have the knowledge to fully understand the potential risk from future medical claims for the group 154 and need to set the rate to cover this unknown risk. In that case, the insurer 150 would like to use the PHI 136 from the group 154 to assess the risk of claims and set the group health insurance premium appropriately. Unfortunately, the group 154 may also be too large for the insurance company 150 to practically obtain permission from each person in the group, without which HIPAA prohibits the healthcare providers 138 from releasing the PHI 136 to the insurer 150. The de-identified data 140, which the healthcare providers or other source sites 138 could release without permission, is not useful to the insurer 150 because the insurer has no way to know whether it corresponds to the people in the group 154. With no way to obtain medical history data for the group, the insurer 150 cannot set the group insurance premium acceptably.

[017] Referring to FIG. 2, to provide the insurer 150 with the medical history information necessary to calculate the insurance premium for the group 154, without revealing the protected health information of persons in the group 154, the exemplary system 200 associates unique tokens 202 with the irreversibly de-identified data 140. The tokens 202 correspond to persons treated by healthcare providers but do not reveal the identities of the treated individuals. The insurer 150 can send a data request 203 to a third party 205, who in turn can generate request tokens 204, one for each person in the group 154. The third party 205 can send the request tokens 204 to a data aggregator 206.

Datavant Exhibit 1002

The data aggregator 206 stores de-identified data 140 and associated tokens 202. By searching for the request tokens 204 among the stored tokens 202, the data aggregator 206 can process the de-identified data to generate requested de-identified data 208 that corresponds to the group 154. A data processor 210 can process the requested de-identified data 208 to generate a report 212 containing metrics such as underwriting scores that are useful to the insurer 150 in assessing the overall risk of insuring the group 154.

[018] By using the tokens 202 and request tokens 204, no parties other than the authorized source sites 138 can associate de-identified data 140 with the identity of any person in the group of patients 134 or insureds (e.g., the group 154). The insurer 150 requesting the report 212 can never receive data associated with individuals. Further, the information in the report 212 may be processed into metrics that characterize a large group and cannot be used to infer information about individuals. De-identified data records may be provided to the data processor 210 (e.g., a third part data processor), but that third party may not have access to any personally identifiable information 118 about the group 154. Nor may any party with access to the de-identified data 140, other than the healthcare providers 138, also have access to the de-identifier 142. These features of the system 200 maintain the privacy of the protected health information 130.

[019] While we describe a system in which an insurer 150 needs to estimate the risk of insuring a group of potential customers, the system 200 can work for applications in which information characterizing a group needs to be generated from the private data of group members. In one arrangement, the system may implement Microsoft Windows-based computers in connection with internet-based components. However, other implementations may use other types of components that support the processing of medical history information from healthcare databases.

[020] Referring to FIG. 3, in an exemplary system 300, a user 302 specifies a group of people using identifying data for each group member. Referring briefly to FIG. 4, an exemplary set of identifying data 404 is illustrated. Returning to FIG. 3, the user may obtain the personally identifiable information from a database 304 by retrieving it in

Datavant Exhibit 1002

the form of a group file 330. The user 302 generates a request message, which may be a computer file, which uniquely identifies each member of the group using the identifying data 304. Typically, the group contains at least a minimum number of unique members. A request message 306 may be generated at a remote computer operated by the user 302.

[021] The request message 306 contains a set of identifying data 404 (see FIG. 4) for each group member, as well as data that identifies a user 402 (see FIG. 4), such as the user's name, email address, phone number and facsimile number, and a batch number that identifies the request. The group members' identifying data 404 (see FIG. 4) may include first name, last name, date of birth, gender, and zip code as well as other identifiers, such as social security number, that may be added to ensure that members are uniquely identified. In some examples, fewer identifiers may be used. The request message 306 may also include optional indications that the user 302 requests a particular type of report 212 or requests additional processing to enhance the value of the report.

[022] The request message 306 is sent over a communications network 310 (e.g., the Internet, a LAN, etc.) to an encryption server 312. If the request message 306 contains a minimum number of group members, the encryption server 312 creates a unique token, or identifier, for each person in the message 306. The encryption server creates each token by applying a token generator 314 that encrypts the personally identifiable information of each group member. The set of tokens corresponding to all the group members constitutes a batch of request tokens 204. The minimum number of group members, for example ten, is chosen to make it effectively impossible to associate individual group members with individual tokens in the batch of request tokens 204.

[023] The encryption server 312 provides the request tokens 204 to the de-identified data server 318. The de-identified data server 318 stores records of de-identified data and corresponding tokens 320 obtained from source sites 138 such as pharmacies, healthcare professionals and electronic claims clearing houses. Each token obtained from the source sites 138 may have been created using the same token generator 314 used by the encryption server 312, or using any other means that generates the identical token for the same personally identifiable information.

Datavant Exhibit 1002

[024] For example, a pharmacy tracks the prescription histories of the patients being served. De-identified prescription histories and corresponding tokens are sent to the de-identified data server 318. At the request of a user 302, such as an insurance company, the encryption server 312 generates tokens identical to the patients' tokens using the same personally identifiable information. A unique token corresponding to the same personally identifiable information permits the pharmacy and the insurance company to refer to the same anonymous people without the insurance company ever associating protected health information with a particular person. To produce tokens and request tokens, one or more encryption techniques may be utilized, for example, hash functions and other methodologies may be implemented.

[025] A token matcher 326, executed by the de-identified data server 318, performs a look-up in the de-identified database 320 to find all tokens in the database that match the tokens sent from the encryption server 312. All available data for matched tokens, the requested de-identified data 208, is retrieved for use in the report generator 328. The de-identified data may include, for example, prescription history, medical claims, and hospital claims. The de-identified data server 318, or the data processor 210 may use the report generator 328 to process the requested de-identified data 208 in a way that leaves it irreversibly de-identified. An example of such processing is an underwriting algorithm that transforms the data into an underwriting assessment. The report generator formats the processed data into an electronic or hardcopy report 212 that is returned to the user.

[026] While the report 212 is described as generated on a computer system, it may also be generated in part or entirely outside the computer system. For example, the report 212 could be conveyed to the user via regular mail or other similar technique. In particular, the report may be generated and printed at the site of the de-identified data server 318 and subsequently communicated to the user 302 without using the computer network. The report generator 328 may also reside in the data processor 210 separate from the de-identified data server 318.

Datavant Exhibit 1002

[027] In one arrangement, once the relevant information and options have been selected, the user 302 submits the request by clicking a submit button. The request message 306 may be encrypted prior to being transmitted over a computer network 310. At the encryption server 312, the request message 306 is unencrypted and stored. The encryption server 312 may send an optional confirmation message to the user 302. The confirmation message may include the time and date that the message was received, and may indicate the service level and options selected by the user 302.

[028] Referring to FIG. 4, the user 302 can input the user's identifying information 402, including name, email address, phone number and/or facsimile number, in the first record, or set of fields, of the request message 306. The user can then input the personally identifiable information 404 for each of the group members, including first name, last name, gender, date of birth, and zip code. Equivalently, the user can incorporate the group file 330 into the request message 306. Information about the insurance policy 408 for which the group has applied, or other insurance purpose for which the report 212 is being requested may also be included in the request message 306. The format of the request message 306 may be adjusted based on the user's 302 needs.

[029] The request message 306 may also include information about the level of service 410 requested by the user 302, for example the quantity, quality or type of information. A first level of service may request up to six months of medical history; a second level may request up to twelve months of history; and a third level may request a two year medical history. Alternatively, instead of providing the user 302 with a variety of service level options 410, the system 300 may simply retrieve all of the medical history information available for the group.

[030] The user 302 may also request additional, optional information 412. For example, the user 302 may request information regarding the drug categories and drug indications associated with the drugs in the de-identified data. Drug indications include the medical conditions associated with each drug. Drug categories include the type of drug. This data can be passed to the data processor 210 to include in the report 212. Alternatively, this data may be returned as part of every report 212.

Datavant Exhibit 1002

[031] Referring to FIG. 5, a flowchart 500 represents a particular arrangement of operations of a token generator (e.g., the token generator 314 shown in FIG. 3). Operations include receiving 502 the request message (e.g., request message 306) containing the personally identifiable information of each person in the group (e.g., such as the group 154 shown in FIG. 1). Upon receiving the request message, operations may also include determining 504 whether the message includes the minimum number of persons. If the message does not include the minimum number of persons, the token generator returns to receive 502 a request message. A limit on the minimum number of persons ensures that a report (e.g., the report 212) covers enough people such that it is difficult (if not impossible) to infer any association between particular persons and the information in the report. If the message does include the minimum number of people, operations of the token generator include producing 508 tokens from the identifying data of each person. Producing the tokens may include applying an encryption algorithm to the identifying data of each person. The tokens uniquely identify each person in the group 154.

[032] Operations also include determining 510 if the request message includes a batch number. If the message does not include a batch number, operations include generating 512 a batch number. Operations also include providing 516 the tokens, batch number and report options. The individual tokens are placed in a batch file and may be encrypted before being transmitted over the network.

[033] Each batch file of request tokens 204 also specifies the information needed for the report 212. The request tokens are transmitted to the de-identified data server 318, unencrypted and processed using rules for searching, matching, and retrieving healthcare data.

[034] Referring to FIG. 6, a flowchart 600 represents a particular arrangement of operations of a token matcher (e.g., the token matcher 326 shown in FIG. 3). Operations include receiving 602 request tokens (e.g., such as the request tokens 204 shown in FIG. 2). Operations may also include receiving 604 a token (e.g., such as the token 202) and associated de-identified data (e.g., such as the de-identified data 140), typically from

Datavant Exhibit 1002

source sites (e.g., such as the source site 138 shown in FIG. 1). Upon receiving a request token, de-identified data and a token, operations include determining 606 whether the request token matches the token. If no match is found, operations include returning to receive 604 more tokens and de-identified data. If a match is found, operations include processing 608 the de-identified data. Processing may include storage for later retrieval. In some arrangements, operations may also include determining whether a minimum number of matches has been detected. If such a minimum number of matches has not occurred in comparing the request tokens and the tokens, action may be taken (e.g., pause or restart processing) until the predefined number of matches has been detected (e.g., so as not to increase the probability of one or more individuals being identified by a process of elimination).

[035] The de-identified data (e.g., such as the de-identified data 140) may include a list of drugs prescribed over the requested period for the members of the group (e.g., such as the group 154). The list of drugs prescribed may include the drug name, form, strength, days supplied, and date dispensed. As part of processing 608 the de-identified data, operations may include determining the drug category and drug indications for each drug prescribed. Operations may also include accessing a database relating the drug category and indications to each possible drug. The database may be maintained within the de-identified data server 318 database, or may be accessed on a remote server maintained by a third party.

[036] Upon processing the de-identified data, operations also include determining 610 if additional tokens remain in the batch of request tokens (e.g., such as the request tokens 204). If additional tokens remain, operations include receiving 602 more request tokens. If there are no additional request tokens, operations may include outputting 612 the processed, de-identified data.

[037] Operations may also include providing the number of tokens submitted, the number matched, and the overall match rate. The collected data covers the interval of historical data according to the level of service requested (e.g., as represented by the level of service 410 in FIG. 4). De-identified diagnosis and procedures data may also be

Datavant Exhibit 1002

included from administrative medical claims from a doctor's office (e.g., office 106) or a healthcare facility (e.g., the hospital 108).

[038] In addition to accessing and incorporating drug indication information for each drug prescribed to persons in the group (e.g., such as group 154), operations may include further processing of the requested de-identified data. For instance, operations may include determining the probability that a particular drug indicates a particular condition. In this example, in addition to providing the possible indications, the requested de-identified data would include the likelihood that anonymous individuals associated with the request tokens (e.g., such as request tokens 204) have each of the conditions indicated by the prescribed drugs. Operations may also include using expert rule systems to provide health status information based on the prescription drug history information. Alternatively, operations may include using diagnosis codes from medical claims data to assess health status.

[039] The requested de-identified data 208 may be sent for further processing to a third party data processor (e.g., data processor 210) who may apply proprietary algorithms, modify the data format, or generate additional reports, provided that no re-identifiable information is transmitted to the user 302. Third parties may not have access to the request message 306 and the group file 330 so that no association may be inferred between the de-identified data 140 and particular persons in the group 154.

[040] The report 212 provides the insurer 150 with information for making an immediate, informed decision about the insurance related risks. In particular, the insurer 150 may accept, reject or adjust the group's insurance rating depending on the information in the report 212. Actuarial tables and formulas may be used to determine which of the insurance actions are taken. The report 212 may be used alone to make decisions about the insurability of the group 154, or may simply indicate that additional investigation is needed.

[041] FIG. 7 is a schematic diagram of a generic computer system 700. The system 700 can be used for the operations described in association with any of the computer-implemented methods described previously, according to one implementation.

Datavant Exhibit 1002

The system 700 includes a processor 710, a memory 720, a storage device 730, and an input/output device 740. Each of the components 710, 720, 730, and 740 are interconnected using a system bus 750. The processor 710 is capable of processing instructions for execution within the system 700. In one implementation, the processor 710 is a single-threaded processor. In another implementation, the processor 710 is a multi-threaded processor. The processor 710 is capable of processing instructions stored in the memory 720 or on the storage device 730 to display graphical information for a user interface on the input/output device 740.

[042] The memory 720 stores information within the system 700. In some implementations, the memory 720 is a computer-readable medium. The memory 720 is a volatile memory unit in some implementations and is a non-volatile memory unit in other implementations.

[043] The storage device 730 is capable of providing mass storage for the system 700. In one implementation, the storage device 730 is a computer-readable medium. In various different implementations, the storage device 730 may be a floppy disk device, a hard disk device, an optical disk device, or a tape device.

[044] The input/output device 740 provides input/output operations for the system 700. In one implementation, the input/output device 740 includes a keyboard and/or pointing device. In another implementation, the input/output device 740 includes a display unit for displaying graphical user interfaces.

[045] The features described can be implemented in digital electronic circuitry, or in computer hardware, firmware, software, or in combinations of them. The apparatus can be implemented in a computer program product tangibly embodied in an information carrier, e.g., in a machine-readable storage device, for execution by a programmable processor; and method steps can be performed by a programmable processor executing a program of instructions to perform functions of the described implementations by operating on input data and generating output. The described features can be implemented advantageously in one or more computer programs that are executable on a programmable system including at least one programmable processor coupled to receive

Datavant Exhibit 1002

data and instructions from, and to transmit data and instructions to, a data storage system, at least one input device, and at least one output device. A computer program is a set of instructions that can be used, directly or indirectly, in a computer to perform a certain activity or bring about a certain result. A computer program can be written in any form of programming language, including compiled or interpreted languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, or other unit suitable for use in a computing environment.

[046] Suitable processors for the execution of a program of instructions include, by way of example, both general and special purpose microprocessors, and the sole processor or one of multiple processors of any kind of computer. Generally, a processor will receive instructions and data from a read-only memory or a random access memory or both. The essential elements of a computer are a processor for executing instructions and one or more memories for storing instructions and data. Generally, a computer will also include, or be operatively coupled to communicate with, one or more mass storage devices for storing data files; such devices include magnetic disks, such as internal hard disks and removable disks; magneto-optical disks; and optical disks. Storage devices suitable for tangibly embodying computer program instructions and data include all forms of non-volatile memory, including by way of example semiconductor memory devices, such as EPROM, EEPROM, and flash memory devices; magnetic disks such as internal hard disks and removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks. The processor and the memory can be supplemented by, or incorporated in, ASICs (application-specific integrated circuits).

[047] To provide for interaction with a user, the features can be implemented on a computer having a display device such as a CRT (cathode ray tube) or LCD (liquid crystal display) monitor for displaying information to the user and a keyboard and a pointing device such as a mouse or a trackball by which the user can provide input to the computer.

[048] The features can be implemented in a computer system that includes a back-end component, such as a data server, or that includes a middleware component,

Datavant Exhibit 1002

such as an application server or an Internet server, or that includes a front-end component, such as a client computer having a graphical user interface or an Internet browser, or any combination of them. The components of the system can be connected by any form or medium of digital data communication such as a communication network. Examples of communication networks include, e.g., a LAN, a WAN, and the computers and networks forming the Internet.

[049] The computer system can include clients and servers. A client and server are generally remote from each other and typically interact through a network, such as the described one. The relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other.

[050] A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the following claims.

Datavant Exhibit 1002

WHAT IS CLAIMED IS:

1. A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals;

producing, by a processor, a request token for each individual included in the group;

comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens;

producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

2. The computer-implemented method of claim 1, wherein the provided healthcare information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

3. The computer-implemented method of claim 1, wherein receiving the request for healthcare information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

4. The computer-implemented method of claim 1, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

5. The computer-implemented method of claim 1, in which the tokens associated with healthcare data and the request tokens are similarly encrypted.

6. The computer-implemented method of claim 1, in which the healthcare data represents medical related information associated with the individuals of the group.

7. A system comprising:

a data server for producing healthcare information that characterizes a group of multiple individuals identified in a request for the healthcare information that

Datavant Exhibit 1002

characterizes the group, wherein a request token is produced for each individual included in the group, the data server is configured to compare the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens, the produced healthcare information is absent personally identifiable information and is based on a minimum number of matched tokens, the data server is also configured to provide the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

8. The system of claim 7, wherein the provided healthcare information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

9. The system of claim 7, wherein the request for healthcare information that characterizes a group of individuals includes personally identifiable information associated with the individuals of the group.

10. The system of claim 7, in which the data that identifies each individual is encrypted.

11. The system of claim 7, in which the tokens associated with the healthcare data and the request tokens are similarly encrypted.

12. The system of claim 7, in which the data server provides the requested healthcare information if the group includes at least a minimum number of individuals.

13. The system of claim 7, in which the healthcare data represents medical related information associated with the individuals of the group.

14. One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals;

producing, by a processor, a request token for each individual included in the group;

Datavant Exhibit 1002

comparing the request tokens to tokens associated with healthcare data that includes de-identified information to find matching tokens;

producing the healthcare information with the identity of the individuals being unattainable from the produced healthcare information based on a minimum number of matched tokens; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the individuals in the group.

15. The computer readable storage devices of claim 14, wherein the provided healthcare information is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

16. The computer readable storage devices of claim 14, wherein receiving the request for healthcare information that characterizes the group of individuals includes receiving personally identifiable information associated with the individuals of the group.

17. The computer readable storage devices of claim 14, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

18. The computer readable storage devices of claim 14, in which the tokens associated with the healthcare data and the request tokens are similarly encrypted.

19. The computer readable storage devices of claim 14, in which the healthcare data represents medical related information associated with the individuals of the group.

20. The computer readable storage devices of claim 14, in which producing the requested healthcare information includes determining if the group includes at least a minimum number of individuals.

Datavant Exhibit 1002

ABSTRACT

A computer-implemented method includes producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals. The identity of the individuals is unattainable from the produced information. The method also includes providing the produced information to report the characteristics of the group.

Datavant Exhibit 1002

100
Source Sites
138
Claims Clearing House
137
Claims Warehouse
139
Protected Health Information
136
De-identifier
142
De-identified Data
140
claims
105
Pharmacy
110
Hospital
108
Healthcare Professional
106
Employer
152
Insurer
150
Jack
102
154
156
104
114
116
120
122
124
126
128
118
112
130
134
Illness, treatment, . . . , name1, name2, DOB, gender, ZIP
Illness, treatment, . . . , name1, name2, DOB, gender, ZIP
Illness, treatment, . . . , name1, name2, DOB, gender, ZIP

FIG. 1



200
138
Source Sites
Healthcare Professional
Claims Clearing Houses
Pharmacies
134
Group of Patients
214
202
token, de-identified data
token, de-identified data
token, . . .
. . .
140
202
Tokens
De-identified data
206
Data Aggregator
204
Request Tokens
205
Third Party
203
Data Request
150
Insurer
154
Group of Insureds
208
Requested de-identified data
210
Data Processor
212
Report

FIG. 2



Encryption Server
300
312
314
Token Generator
310
204
Request Tokens
306
Request Message
De-identified Data Server
318
326
302
User
Token Matcher
Report Generator
328
Report
330
212
320
Group File
304
De-identified Data and Tokens
Identifying Data
140
202
De-identified Data
Tokens
138
Source Sites

FIG. 3



306
REQUEST MESSAGE
402
user's name, user's email address, user's phone number, user's facsimile number, . . .
404
first name 1, last name 1, gender 1, date of birth 1, zip code 1, . . .
first name 2, last name 2, gender 2, date of birth 2, zip code 2, . . .
first name 3, last name 3, gender 3, date of birth 3, zip code 3, . . .
. . .
first name N, last name N, gender N, date of birth N, zip code N, . . .
406
batch number
408
type of insurance policy
410
level of service requested
412
optional report content requested

FIG. 4



500
502
Receive request message containing personally identifiable information
504
Minimum number of persons?
N
Y
508
Produce tokens from personally identifiable information
510
Does request message include batch number?
N
512
Generate batch number
Y
516
Provide tokens, batch number, and report options

FIG. 5



600
602
Receive request tokens
604
Receive tokens plus associated de-identified data
606
Tokens match?
N
Y
608
Process de-identified patient data
610
Additional token?
Y
N
612
Output processed, de-identified data

FIG. 6



Input/Output Devices
740
720
Memory
750
Input/Output
Storage Device
730
Processor
710
700

FIG. 7

NONPUBLICATION REQUEST UNDER 35 U.S.C. 122(b)(2)(B)(i)		
	First Named Inventor	Andrew L. Paris III
	Title	De-identifying medical history information for medical underwriting
	Attorney Docket Number	25412-0002002

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.

I hereby request that the attached application not be published under 35 U.S.C. 122(b).

/Jeffrey J. Barclay, Reg. No. 48,950/	5 June 2015
Signature	Date
Jeffrey J. Barclay	48,950
Typed or printed name	Registration Number, if applicable
Telephone Number	

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**

PTO/AIA/14 (12-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	25412-0002002
	Application Number	
Title of Invention	De-identifying medical history information for medical underwriting	

The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.

Secrecy Order 37 CFR 5.2

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Inventor 1 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Andrew	L.	Paris	III

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	Victor	State/Province	NY	Country of Residence i	US

Mailing Address of Inventor:

Address 1	559 Fox Hunt Drive		
Address 2			
City	Victor	State/Province	NY
Postal Code	14564	Country i	US

All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the **Add** button. Add

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below.
For further information see 37 CFR 1.33(a).

☐ **An Address is being provided for the correspondence Information of this application.**

Customer Number	26161		
Email Address		Add Email	Remove Email

Application Information:

Title of the Invention	De-identifying medical history information for medical underwriting		
Attorney Docket Number	25412-0002002	Small Entity Status Claimed	☒
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)	7	Suggested Figure for Publication (if any)	

Filing By Reference :

Datavant Exhibit 1002

PTO/AIA/14 (12-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	25412-0002002
	Application Number	
Title of Invention	De-identifying medical history information for medical underwriting	

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

☒ **Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not** be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select One:	◉ Customer Number	○ US Patent Practitioner	○ Limited Recognition (37 CFR 11.9)
Customer Number	26161		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
When referring to the current application, please leave the application number blank.

Prior Application Status	Pending		Remove
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
	Continuation of	12827745	2010-06-30
Prior Application Status	Expired		Remove
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
12827745	Claims benefit of provisional	61222428	2009-07-01

Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button. Add

Datavant Exhibit 1002

PTO/AIA/14 (12-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	25412-0002002
	Application Number	
Title of Invention	De-identifying medical history information for medical underwriting	

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(d). When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX) [i]the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(h)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

Remove

Application Number	Country [i]	Filing Date (YYYY-MM-DD)	Access Code[i] (if applicable)

Additional Foreign Priority Data may be generated within this form by selecting the **Add** button. Add

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.
NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

Authorization to Permit Access:

☐ Authorization to Permit Access to the Instant Application by the Participating Offices

PTO/AIA/14 (12-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	25412-0002002
	Application Number	
Title of Invention	De-identifying medical history information for medical underwriting	

If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the instant patent application is filed access to the instant patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the instant patent application is filed to have access to the instant patent application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect to: 1) the instant patent application-as-filed; 2) any foreign application to which the instant patent application claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the instant patent application; and 3) any U.S. application-as-filed from which benefit is sought in the instant patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing this Authorization.

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant 1 Remove

If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.

Clear

◯ Assignee	◯ Legal Representative under 35 U.S.C. 117	◯ Joint Inventor
◯ Person to whom the inventor is obligated to assign.	◯ Person who shows sufficient proprietary interest	

If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:

Name of the Deceased or Legally Incapacitated Inventor :

If the Applicant is an Organization check here. ☐

Prefix	**Given Name**	Middle Name	**Family Name**	Suffix

PTO/AIA/14 (12-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	25412-0002002
	Application Number	
Title of Invention	De-identifying medical history information for medical underwriting	

Mailing Address Information:			
Address 1			
Address 2			
City		**State/Province**	
Country i		Postal Code	
Phone Number		Fax Number	
Email Address			

Additional Applicant Data may be generated within this form by selecting the Add button. Add

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not subsitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Assignee 1

Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication . An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.

Remove

If the Assignee or Non-Applicant Assignee is an Organization check here. ☒

Organization Name	Vigilytics LLC

Mailing Address Information For Assignee including Non-Applicant Assignee:

Address 1	559 Fox Hunt Drive		
Address 2			
City	Victor	**State/Province**	NY
Country i	US	Postal Code	14564
Phone Number		Fax Number	
Email Address			

Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button. Add

Remove

Signature:

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications

Signature	/Jeffrey J. Barclay, Reg. No. 48,950/	Date (YYYY-MM-DD)	2015-06-05

Datavant Exhibit 1002

PTO/AIA/14 (12-13)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	25412-0002002
	Application Number	
Title of Invention	De-identifying medical history information for medical underwriting	

First Name	Jeffrey	Last Name	Barclay	Registration Number	48950

Additional Signature may be generated within this form by selecting the Add button. Add

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Datavant Exhibit 1002

Electronic Patent Application Fee Transmittal

Application Number:	
Filing Date:	
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris III
Filer:	Jeffrey J. Barclay/Matthew Doherty
Attorney Docket Number:	25412-0002002

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Utility application filing	1011	1	280	280
Utility Search Fee	1111	1	600	600
Utility Examination Fee	1311	1	720	720
Pages:				
Claims:				
Miscellaneous-Filing:				
Late Filing Fee for Oath or Declaration	1051	1	140	140
Petition:				

Datavant Exhibit 1002

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	1740

Electronic Acknowledgement Receipt

EFS ID:	22554433
Application Number:	14732358
International Application Number:	
Confirmation Number:	3202
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris III
Customer Number:	26161
Filer:	Jeffrey J. Barclay/mary ann reed
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002002
Receipt Date:	05-JUN-2015
Filing Date:	
Time Stamp:	17:46:43
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$1740
RAM confirmation Number	4505
Deposit Account	061050
Authorized User	FISH & RICHARDSON P C

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Datavant Exhibit 1002

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal of New Application	PAP.pdf	79780 a603470ac2208c0a43883c0f47f0776fa210	no	2
Warnings:					
Information:					
2		Application.pdf	155765 5696cb34fd4a0ae0f060d6bea471a5e9ee1	yes	20

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Specification	1	16
	Claims	17	19
	Abstract	20	20

Warnings:					
Information:					
3	Drawings-only black and white line drawings	Figs.pdf	167208 ee9621f6b68a15779aafb3bc974054a6313	no	7
Warnings:					
Information:					
4	Nonpublication request from applicant	Nonpublication.pdf	59478 cf2f02831b25b89c3e45cdc81176918464fd	no	1
Warnings:					
Information:					
5	Application Data Sheet	ADS0002002.pdf	1561076 6f66ece4f2612fd1bf36a1d0a1e447911777	no	7
Warnings:					
Information:					
6	Fee Worksheet (SB06)	fee-info.pdf	36491 f88b9460ef06675d60b27453944e8e23b9f	no	2

Datavant Exhibit 1002

Warnings:	
Information:	
Total Files Size (in bytes):	2059798

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

SCORE Placeholder Sheet for IFW Content

Application Number: 14732358 Document Date: 06/05/2015

The presence of this form in the IFW record indicates that the following document type was received in electronic format on the date identified above. This content is stored in the SCORE database.

- Drawings – Other than Black and White Line Drawings

Since this was an electronic submission, there is no physical artifact folder, no artifact folder is recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW record were created from the original documents that are stored in SCORE.

To access the documents in the SCORE database, refer to instructions below.

At the time of document entry (noted above):

- Examiners may access SCORE content via the eDAN interface.
- Other USPTO employees can bookmark the current SCORE URL (http://Score.uspto.gov/ScoreAccessWeb/).
- External customers may access SCORE content via the Public and Private PAIR interfaces.

Form Revision Date: September 30, 2013

Document code: WFEE

United States Patent and Trademark Office
Sales Receipt for Accounting Date: 06/15/2015

VVAN11	SALE	#00000024	Mailroom Dt:	06/05/2015	061050	14732358	
		01	FC : 4011	70.00 DA			
		02	FC : 2111	300.00 DA			
		03	FC : 2311	360.00 DA			
		04	FC : 2051	70.00 DA			

Document code: WFEE

United States Patent and Trademark Office
Sales Receipt for Accounting Date: 06/15/2015

VVAN11 ADJ #00000013 Mailroom Dt: 06/05/2015
Seq No: 4505 Sales Acctg Dt: 06/08/2015 061050 14732358

01	FC : 1011	280.00	CR
02	FC : 1111	600.00	CR
03	FC : 1311	720.00	CR
04	FC : 1051	140.00	CR